


**CUMULATIVE
SUPPLEMENT 3
MARCH 2014**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Medical Products and Tobacco
Office of Generic Drugs**

2014

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

Cumulative Supplement 3

March 2014

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition	vi
1.6 Report of Counts for the Prescription Drug Product List	vii
1.7 Cumulative Supplement Legend	viii
DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

34th EDITION

**CUMULATIVE SUPPLEMENT 3
March 2014**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
WEST WARD INC (WEST WARD)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS CORP)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2013</u>	<u>MAR 2014</u>	<u>JUN 2014</u>	<u>SEPT 2014</u>	<u>DEC 2014</u>
DRUG PRODUCTS LISTED	15711	15885			
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)			
MULTISOURCE	13194 (84.0%)	13345 (84.0%)			
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%)			
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)			
EXCEPTIONS ¹	78 (0.5%)	78 (0.5%)			
NEW MOLECULAR ENTITIES APPROVED	20	12			
NUMBER OF APPLICANTS	866	873			

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.

CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL
ACAMPROSATE CALCIUM

AB MYLAN PHARMS INC 333MG A200142 001 Mar 11, 2014 Feb NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>D> AA MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar DISC
>A> @ 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar DISC
>D> AA VINTAGE PHARMS 325MG;50MG;40MG A040511 001 Aug 27, 2003 Mar CRLD
>A> AA + 325MG;50MG;40MG A040511 001 Aug 27, 2003 Mar CRLD
@ WATSON LABS 500MG;50MG;40MG A040267 001 Jul 30, 1998 Jan DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

PHRENILIN WITH CAFFEINE AND CODEINE

>D> AB VALEANT 325MG;50MG;40MG;30MG A074911 001 Aug 22, 2001 Mar DISC
>A> @ 325MG;50MG;40MG;30MG A074911 001 Aug 22, 2001 Mar DISC

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA @ MALLINCKRODT 500MG/15ML;7.5MG/15ML A040418 001 Jun 27, 2001 Jan DISC
VINTAGE PHARMS 325MG/15ML;7.5MG/15ML A040894 001 Jul 19, 2011 Feb CAHN

TABLET;ORAL

ANEXSIA

@ MALLINCKRODT 500MG;5MG A089160 001 Apr 23, 1987 Jan DISC
@ 750MG;10MG A040468 001 Oct 31, 2002 Jan DISC

ANEXSIA 7.5/650

@ MALLINCKRODT 650MG;7.5MG A089725 001 Sep 30, 1987 Jan DISC

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA @ MALLINCKRODT 500MG;5MG A040084 002 Jun 01, 1995 Jan DISC
@ 500MG;7.5MG A040201 001 Feb 27, 1998 Jan DISC
@ 500MG;10MG A040201 002 Feb 27, 1998 Jan DISC
@ 650MG;10MG A040084 004 Oct 16, 1996 Jan DISC
@ 660MG;10MG A040084 003 Jul 29, 1996 Jan DISC
@ 750MG;7.5MG A040084 001 Jun 01, 1995 Jan DISC
AA VINTAGE PHARMS 300MG;5MG A090415 001 Jan 24, 2011 Feb CAHN
AA 300MG;7.5MG A090415 002 Jan 24, 2011 Feb CAHN
AA 300MG;10MG A090415 003 Jan 24, 2011 Feb CAHN
@ 650MG;7.5MG A040155 001 Apr 14, 1997 Jan DISC
@ 750MG;7.5MG A040157 001 Apr 12, 1996 Jan DISC
@ WATSON LABS 500MG;7.5MG A081080 001 Aug 30, 1991 Jan DISC
@ 750MG;7.5MG A081083 001 Aug 30, 1991 Jan DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE AND ACETAMINOPHEN

@ MALLINCKRODT 500MG;5MG A040257 001 Aug 04, 1998 Jan DISC
@ WATSON LABS 500MG;5MG A040234 001 Oct 30, 1997 Jan DISC

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

@ WATSON LABS 500MG;7.5MG A040371 001 Dec 29, 2000 Jan DISC
@ 650MG;10MG A040371 002 Dec 29, 2000 Jan DISC

PERCOCET

@ VINTAGE PHARMS LLC 500MG;7.5MG A040341 001 Jul 26, 1999 Jan DISC
@ 650MG;10MG A040341 002 Jul 26, 1999 Jan DISC

>A> TABLET, EXTENDED RELEASE;ORAL
>A> XARTEMIS XR
>A> + MALLINCKRODT INC 325MG;7.5MG N204031 001 Mar 11, 2014 Mar NEWA

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

>A> AB APOTEX INC 325MG;37.5MG A078778 001 Apr 07, 2014 Mar NEWA

ACETYLCYSTEINESOLUTION; INHALATION, ORAL
ACETYLCYSTEINE

AN	INNOPHARMA LICENSING	10%	A204674	001	Feb 11, 2014	Jan	NEWA
----	----------------------	-----	---------	-----	--------------	-----	------

ACYCLOVIRCAPSULE; ORAL
ACYCLOVIR

AB	CADILA PHARMS LTD	200MG	A201445	001	Mar 06, 2014	Feb	NEWA
----	-------------------	-------	---------	-----	--------------	-----	------

ACYCLOVIR SODIUMINJECTABLE; INJECTION
ACYCLOVIR SODIUM

+	BEDFORD	EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Feb	CRLD
@	HIKMA MAPLE	EQ 1GM BASE/VIAL	A074913	002	Oct 15, 1997	Feb	DISC
@		EQ 500MG BASE/VIAL	A074913	001	Oct 15, 1997	Feb	DISC

ADENOSINEINJECTABLE; INJECTION
ADENOSINE

>A>	AP	AGILA SPECLTS	3MG/ML	A078640	001	Mar 21, 2014	Mar	NEWA
	AP		3MG/ML	A078686	001	May 13, 2009	Feb	CAHN
>A>	AP	HOSPIRA INC	3MG/ML	A203883	001	Mar 24, 2014	Mar	NEWA
>A>	AP	SAGENT STRIDES	3MG/ML	A090212	001	Mar 28, 2014	Mar	NEWA

ALPRAZOLAMTABLET; ORAL
ALPRAZOLAM

AB	VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb	CAHN
AB		0.5MG	A090248	002	Sep 17, 2010	Feb	CAHN
AB		1MG	A090248	003	Sep 17, 2010	Feb	CAHN
AB		2MG	A090248	004	Sep 17, 2010	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL
ALPRAZOLAM

AB	ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan	CAHN
	@	0.5MG	A077979	001	Feb 28, 2007	Jan	CAHN
AB		1MG	A077725	002	Jul 31, 2006	Jan	CAHN
	@	1MG	A077979	002	Feb 28, 2007	Jan	CAHN
AB		2MG	A077725	004	Jul 31, 2006	Jan	CAHN
	@	2MG	A077979	003	Feb 28, 2007	Jan	CAHN
AB		3MG	A077725	003	Jul 31, 2006	Jan	CAHN
	@	3MG	A077979	004	Feb 28, 2007	Jan	CAHN

AMANTADINE HYDROCHLORIDECAPSULE; ORAL
AMANTADINE HYDROCHLORIDE

AB	+	SANDOZ	100MG	A071293	001	Feb 18, 1987	Feb	CRLD
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Feb	CRLD

AMLODIPINE BESYLATETABLET; ORAL
AMLODIPINE BESYLATE

@	PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	Feb	DISC
@		EQ 5MG BASE	A078131	002	Sep 04, 2007	Feb	DISC
@		EQ 10MG BASE	A078131	003	Sep 04, 2007	Feb	DISC

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUMTABLET; ORAL
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014	Feb	NEWA
AB		EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014	Feb	NEWA
AB		EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014	Feb	NEWA
AB		EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014	Feb	NEWA
AB		EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014	Feb	NEWA
AB		EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014	Feb	NEWA
AB		EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014	Feb	NEWA
AB		EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014	Feb	NEWA
AB		EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014	Feb	NEWA
AB		EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014	Feb	NEWA
AB		EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014	Feb	NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS
AMMONIA N 13

>A>	AP	UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204496	001	Mar 28, 2014	Mar	NEWA
	AP	WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204506	001	Feb 07, 2014	Jan	NEWA

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	SANDOZ	500MG, N/A, N/A, N/A, 500MG, N/A, N/A, N/A, 30MG	A202588	001	Mar 04, 2014	Feb	NEWA
----	--------	--	---------	-----	--------------	-----	------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

>A>		CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL						
>A>		OMEPRazole AND CLARITHROMYCIN AND AMOXICILLIN						
>A>	+	GASTROENTERO	500MG, N/A, N/A, N/A, 500MG, N/A, N/A, N/A, 20MG	N050824	001	Feb 08, 2011	Mar	CDFR
>D>		CAPSULE, TABLET, CAPSULE, DELAYED RELEASE, TABLET; ORAL						
>D>		OMEPRazole AND CLARITHROMYCIN AND AMOXICILLIN						
>D>	+	GASTROENTERO	500MG, N/A, N/A, N/A, 500MG, N/A, N/A, N/A, 20MG	N050824	001	Feb 08, 2011	Mar	CDFR

AMPICILLIN SODIUM

INJECTABLE; INJECTION
AMPICILLIN SODIUM

>A>	AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A202198	001	Apr 07, 2014	Mar	NEWA
	AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062719	002	May 12, 1987	Feb	CAHN
	AP		EQ 2GM BASE/VIAL	A062797	002	Jul 12, 1993	Feb	CAHN
	AP		EQ 10GM BASE/VIAL	A201404	001	Dec 20, 2013	Jan	CPOT
	AP		EQ 125MG BASE/VIAL	A062797	001	Jul 12, 1993	Feb	CAHN
	AP		EQ 250MG BASE/VIAL	A062719	001	May 12, 1987	Feb	CAHN
	AP		EQ 500MG BASE/VIAL	A062719	003	May 12, 1987	Feb	CAHN
>A>	AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A201025	003	Apr 09, 2014	Mar	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A201025	004	Apr 09, 2014	Mar	NEWA
>A>	AP		EQ 250MG BASE/VIAL	A201025	001	Apr 09, 2014	Mar	NEWA
>A>	AP		EQ 500MG BASE/VIAL	A201025	002	Apr 09, 2014	Mar	NEWA

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION
AMPICILLIN AND SULBACTAM

>A>	AP	AGILA SPECLTS	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A201024	001	Apr 07, 2014	Mar	NEWA
>A>	AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A201024	002	Apr 07, 2014	Mar	NEWA
>A>	AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A202197	001	Apr 07, 2014	Mar	NEWA
	AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A065222	001	Nov 29, 2005	Feb	CAHN
	AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A065222	002	Nov 29, 2005	Feb	CAHN
	AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A065314	001	Nov 27, 2006	Feb	CAHN

APREMILAST

>A>		TABLET; ORAL						
>A>		OTEZLA						
>A>		CELGENE CORP	10MG	N205437	001	Mar 21, 2014	Mar	NEWA
>A>			20MG	N205437	002	Mar 21, 2014	Mar	NEWA
>A>	+		30MG	N205437	003	Mar 21, 2014	Mar	NEWA

ASENAPINE MALEATE

TABLET; SUBLINGUAL
SAPHRIS

		FOREST LABS INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb	CAHN
	+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

>D>	AB	WATSON LABS	325MG; 50MG; 40MG; 30MG	A074359	001	Aug 31, 1995	Mar	DISC
>A>		@	325MG; 50MG; 40MG; 30MG	A074359	001	Aug 31, 1995	Mar	DISC

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

>D>	AB	STEVENS J	385MG;30MG;25MG	A074988	001	Apr 30, 1999	Mar	DISC
>A>		@	385MG;30MG;25MG	A074988	001	Apr 30, 1999	Mar	DISC
>D>	AB		770MG;60MG;50MG	A074988	002	Apr 30, 1999	Mar	DISC
>A>		@	770MG;60MG;50MG	A074988	002	Apr 30, 1999	Mar	DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

>D>	AB	MIRROR PHARMS	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	DISC
>A>		@	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	DISC
>D>	AB	PROSAM LABS	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Mar	DISC
>A>		@	325MG;200MG;16MG	A040283	001	Dec 29, 1998	Mar	DISC

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

>A>	AB	AMNEAL PHARMS	750MG/5ML	A202960	001	Mar 18, 2014	Mar	NEWA
>D>		+	GLAXOSMITHKLINE LLC	N020500	001	Feb 08, 1995	Mar	CFTG
>A>	AB		750MG/5ML	N020500	001	Feb 08, 1995	Mar	CFTG

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

		ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Feb	CAHN
		+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Feb	CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

		ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Feb	CAHN
		+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Feb	CAHN

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

		+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Feb	CTEC
--	--	---	----------------------	--------------	---------	-----	--	-----	------

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

AB		MYLAN	5MG;40MG	A078688	001	Feb 15, 2008	Jan	CTNA
AB			5MG;80MG	A078688	002	Feb 15, 2008	Jan	CTNA

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

>D>	AB	VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Mar	CRLD
>A>	AB	+	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Mar	CRLD
>D>	BT	+	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Mar	CTEC
>A>		+	5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Mar	CTEC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION;TOPICAL

LOTRISONE

AB		+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Jan	CAHN
----	--	---	-------------------	------------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET;ORAL

DUVOID

>D>	AA	WELLSPRING PHARM	10MG	A086262	001		Mar	DISC
>A>		@	10MG	A086262	001		Mar	DISC
>D>	AA		25MG	A086263	001		Mar	DISC
>A>		@	25MG	A086263	001		Mar	DISC
>D>	AA		50MG	A085882	003		Mar	DISC
>A>		@	50MG	A085882	003		Mar	DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINECAPSULE;ORAL
PYLERA

>D>	+	APTALIS PHARMA US	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar	CAHN
>A>	+	FOREST RES INST INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar	CAHN

BROMFENAC SODIUMSOLUTION/DROPS;OPHTHALMIC
BROMDAY

AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan	CFTG
AT1		BROMFENAC SODIUM						
AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan	CTEC
AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan	NEWA
AT1		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan	CTEC

BUDESONIDECAPSULE;ORAL
BUDESONIDE

>A>	AB	BARR LABS DIV TEVA	3MG	A090379	001	Apr 02, 2014	Mar	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		UCERIS						
>D>	+	SALIX PHARMS INC	9MG	N203634	001	Jan 14, 2013	Mar	CAHN
	+		9MG	N203634	001	Jan 14, 2013	Feb	CAHN
>A>	+	SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Mar	CAHN

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL
BUPROPION HYDROCHLORIDE

		@ WATSON LABS	300MG	A077715	002	Jun 13, 2007	Feb	DISC
AB3		ZYDUS PHARMS USA INC	300MG	A201567	001	Jan 17, 2014	Jan	NEWA

BUSPIRONE HYDROCHLORIDETABLET;ORAL
BUSPIRONE HYDROCHLORIDE

AB		ZYDUS PHARMS USA INC	5MG	A078888	001	Feb 07, 2014	Jan	NEWA
AB			10MG	A078888	002	Feb 07, 2014	Jan	NEWA
AB			15MG	A078888	003	Feb 07, 2014	Jan	NEWA
AB			30MG	A078888	004	Feb 07, 2014	Jan	NEWA

CAFFEINE CITRATESOLUTION;INTRAVENOUS
CAFFEINE CITRATE

AP		EXELA PHARMA SCIENCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233	001	Sep 21, 2006	Feb	CAHN
		SOLUTION;ORAL						
		CAFFEINE CITRATE						
AA		EXELA PHARMA SCS LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Feb	CAHN

CALCITRIOLINJECTABLE;INJECTION
CALCITRIOL

		@ TEVA PARENTERAL	0.002MG/ML	A075823	002	Mar 31, 2003	Feb	DISC
--	--	-------------------	------------	---------	-----	--------------	-----	------

CAPTOPRILTABLET;ORAL
CAPTOPRIL

>D>	AB	WATSON LABS	12.5MG	A074451	001	Feb 13, 1996	Mar	DISC
>A>		@	12.5MG	A074451	001	Feb 13, 1996	Mar	DISC
>D>	AB		25MG	A074451	002	Feb 13, 1996	Mar	DISC
>A>		@	25MG	A074451	002	Feb 13, 1996	Mar	DISC
>D>	AB		50MG	A074451	003	Feb 13, 1996	Mar	DISC
>A>		@	50MG	A074451	003	Feb 13, 1996	Mar	DISC
>D>	AB		100MG	A074451	004	Feb 13, 1996	Mar	DISC
>A>		@	100MG	A074451	004	Feb 13, 1996	Mar	DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

>D>		CAPOZIDE 25/15						
>D>	AB	APOTHECON	25MG;15MG	N018709	001	Oct 12, 1984	Mar	DISC
>A>		@	25MG;15MG	N018709	001	Oct 12, 1984	Mar	DISC

TABLET;ORAL							
>D>		CAPOZIDE 25/25					
>D>	AB	+ APOTHECON	25MG;25MG	N018709	002	Oct 12, 1984	Mar DISC
>A>		@	25MG;25MG	N018709	002	Oct 12, 1984	Mar DISC
>D>		CAPOZIDE 50/15					
>D>	AB	+ APOTHECON	50MG;15MG	N018709	004	Oct 12, 1984	Mar DISC
>A>		@	50MG;15MG	N018709	004	Oct 12, 1984	Mar DISC
>D>		CAPOZIDE 50/25					
>D>	AB	APOTHECON	50MG;25MG	N018709	003	Oct 12, 1984	Mar DISC
>A>		@	50MG;25MG	N018709	003	Oct 12, 1984	Mar DISC
CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
>D>	AB	MYLAN	25MG;25MG	A074896	002	Dec 29, 1997	Mar CRLD
>A>	AB	+	25MG;25MG	A074896	002	Dec 29, 1997	Mar CRLD
>D>	AB		50MG;15MG	A074896	004	Dec 29, 1997	Mar CRLD
>A>	AB	+	50MG;15MG	A074896	004	Dec 29, 1997	Mar CRLD

CARBIDOPA

TABLET;ORAL							
CARBIDOPA							
AB		AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Feb NEWA
LODOSYN							
AB	+	ATON	25MG	N017830	001		Feb CFTG

CARBINOXAMINE MALEATE

SOLUTION;ORAL							
CARBINOXAMINE MALEATE							
AA		VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb CAHN
TABLET;ORAL							
CARBINOXAMINE MALEATE							
AA		VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb CAHN

CARBOPLATIN

INJECTABLE;IV (INFUSION)							
CARBOPLATIN							
AP	+	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb CAHN
AP	+		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb CAHN
AP	+		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb CAHN
AP	+		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb CAHN

CARISOPRODOL

TABLET;ORAL							
CARISOPRODOL							
AA		SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan NEWA

CEFACLOR

FOR SUSPENSION;ORAL							
CEFACLOR							
AB	+	YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan CRLD

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION;ORAL							
CEFADROXIL							
		@ ANI PHARMS INC	EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan CAHN
		@	EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan CAHN
		@	EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan CAHN
		@	EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989	Jan CAHN
		@	EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Jan CAHN

CEFAZOLIN SODIUM

INJECTABLE;INJECTION							
CEFAZOLIN SODIUM							
>D>	AP	STERI PHARMA	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar DISC
>A>		@	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar DISC

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION							
CEFTRIAXONE							
AP		AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb CAHN

CEPHALEXINCAPSULE;ORAL
CEPHALEXIN

>D>	AB	STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar	DISC
>A>		@	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar	DISC

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

		@ ANI PHARMS INC	100MG	A088768	001	Oct 11, 1984	Jan	CAHN
		@	100MG	A088812	001	Oct 19, 1984	Jan	CAHN
		@	100MG	A088840	001	Oct 25, 1984	Feb	CAHN
		@	100MG	A088918	001	Oct 16, 1984	Jan	CAHN
AB		@	100MG	A088921	001	Apr 12, 1985	Jan	CAHN
		@	100MG	A089446	001	Nov 17, 1986	Jan	CAHN
		@	250MG	A088813	001	Oct 19, 1984	Jan	CAHN
		@	250MG	A088919	001	Oct 16, 1984	Jan	CAHN
AB		@	250MG	A088922	001	Apr 12, 1985	Jan	CAHN
		@	250MG	A089447	001	Nov 17, 1986	Jan	CAHN
		GLUCAMIDE						
		@ ANI PHARMS INC	250MG	A088641	001	Oct 11, 1984	Jan	CAHN

CICLOPIROX

CREAM;TOPICAL

CICLOPIROX

>D>		@ TARO	0.77%	A076790	001	Apr 12, 2005	Mar	CMFD
>A>	AB	@	0.77%	A076790	001	Apr 12, 2005	Mar	CMFD
		@	0.77%	A076790	001	Apr 12, 2005	Feb	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

AA		ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan	CAHN
		@	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN
		@	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan	CAHN

CIPROFLOXACIN

FOR SUSPENSION;ORAL

CIPRO

AB		BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb	CFTG
AB	+		500MG/5ML	N020780	002	Sep 26, 1997	Feb	CFTG
		CIPROFLOXACIN						
AB		LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb	NEWA
AB			500MG/5ML	A200563	002	Mar 05, 2014	Feb	NEWA

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

AP		PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb	CAHN
----	--	-----------------	--------	---------	-----	--------------	-----	------

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA		AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb	NEWA
----	--	---------------	------------------	---------	-----	--------------	-----	------

CLINDAMYCIN PHOSPHATE

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ VINTAGE PHARMS EQ 1% BASE

A062930 001 Jun 28, 1989 Feb CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

CLONIDINE HYDROCHLORIDE

AP		ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb	NEWA
AP			5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb	NEWA

TABLET, EXTENDED RELEASE;ORAL

CLONIDINE HYDROCHLORIDE

>A>	AB	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar	NEWA
>A>	AB		0.2MG	A202983	002	Apr 02, 2014	Mar	NEWA

CLOPIDOGREL

TABLET; ORAL

CLOPIDOGREL

>A>	AB	AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar	NEWA
-----	----	---------------	------	---------	-----	--------------	-----	------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB		APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb	NEWA
AB		MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan	NEWA

CLOZAPINE

TABLET; ORAL

CLOZAPINE

>D>		IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar	CTEC
>A>	AB		12.5MG	A074949	003	Jul 31, 2003	Mar	CTEC
>D>			200MG	A076809	001	Dec 16, 2005	Mar	CTEC
>A>	AB		200MG	A076809	001	Dec 16, 2005	Mar	CTEC
>A>	AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar	NEWA
>A>	AB		50MG	A075417	004	Apr 15, 2010	Mar	NEWA
>A>	AB		200MG	A075417	005	Apr 15, 2010	Mar	NEWA

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP		SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb	NEWA
----	--	---------------	--------------------	---------	-----	--------------	-----	------

CONIVAPTAN HYDROCHLORIDE

INJECTABLE; IV (INFUSION)

VAPRISOL

@ CUMBERLAND PHARMS 20MG/4ML (5MG/ML)

N021697	001	Dec 29, 2005	Feb	CAHN
---------	-----	--------------	-----	------

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

+ CUMBERLAND PHARMS 20MG/100ML (0.2MG/ML)

N021697	002	Oct 08, 2008	Feb	CAHN
---------	-----	--------------	-----	------

DANTROLENE SODIUM

CAPSULE; ORAL

DANTRIUM

>D>	AB	JHP PHARMS	25MG	N017443	001		Mar	CAHN
>D>	AB		50MG	N017443	003		Mar	CAHN
>D>	AB	+	100MG	N017443	002		Mar	CAHN
>A>	AB	PAR STERILE PRODUCTS	25MG	N017443	001		Mar	CAHN
>A>	AB		50MG	N017443	003		Mar	CAHN
>A>	AB	+	100MG	N017443	002		Mar	CAHN

INJECTABLE; INJECTION

DANTROLENE SODIUM

>D>		US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar	CTNA
>A>		REVONTO						
>A>	AP	US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar	CTNA

DAPAGLIFLOZIN

TABLET; ORAL

FARXIGA

ASTRAZENECA AB

5MG

N202293	001	Jan 08, 2014	Feb	CAHN
---------	-----	--------------	-----	------

+ 10MG

N202293	002	Jan 08, 2014	Feb	CAHN
---------	-----	--------------	-----	------

BRISTOL MYERS SQUIBB

5MG

N202293	001	Jan 08, 2014	Jan	NEWA
---------	-----	--------------	-----	------

+ 10MG

N202293	002	Jan 08, 2014	Jan	NEWA
---------	-----	--------------	-----	------

DECITABINE

POWDER; INTRAVENOUS

DECITABINE

+ SUN PHARMA GLOBAL 50MG/VIAL

N205582	001	Jan 28, 2014	Jan	NEWA
---------	-----	--------------	-----	------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

@ ANI PHARMS INC

25MG

A071800	001	Dec 08, 1987	Jan	CAHN
---------	-----	--------------	-----	------

@ 50MG

A071801	001	Dec 08, 1987	Jan	CAHN
---------	-----	--------------	-----	------

@ 75MG

A071802	001	Dec 08, 1987	Jan	CAHN
---------	-----	--------------	-----	------

@ 100MG

A071803	001	May 29, 1997	Feb	CAHN
---------	-----	--------------	-----	------

@ 150MG

A071804	001	May 29, 1997	Feb	CAHN
---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL
 DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)
 AB SUN PHARMA GLOBAL 0.01MG/SPRAY A078271 001 Dec 23, 2013 Jan CMS2

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL
 DESVENLAFAXINE
 BC SUN PHARMA GLOBAL 50MG N205583 001 Jan 28, 2014 Jan NEWA
 BC + 100MG N205583 002 Jan 28, 2014 Jan NEWA

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL
 DESVENLAFAXINE FUMARATE
 + SUN PHARMA GLOBAL EQ 50MG BASE N205583 001 Jan 28, 2014 Feb CTEC
 + EQ 100MG BASE N205583 002 Jan 28, 2014 Feb CTEC

DEXCHLORPHENIRAMINE MALEATE

TABLET;ORAL
 DEXCHLORPHENIRAMINE MALEATE
 @ ANI PHARMS INC 2MG A088682 001 Jan 17, 1986 Jan CAHN

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
 DEXTROAMPHETAMINE SULFATE
 AA COREPHARMA 5MG A090652 001 Mar 07, 2014 Feb NEWA
 AA 10MG A090652 002 Mar 07, 2014 Feb NEWA

DIAZEPAM

CONCENTRATE;ORAL
 DIAZEPAM
 >A> AA LANNETT HOLDINGS INC 5MG/ML A204433 001 Apr 14, 2014 Mar NEWA
 DIAZEPAM INTENSOL
 >D> + ROXANE 5MG/ML A071415 001 Apr 03, 1987 Mar CFTG
 >A> AA + 5MG/ML A071415 001 Apr 03, 1987 Mar CFTG
 TABLET;ORAL
 DIAZEPAM
 >D> AB DAVA PHARMS INC 2MG A070226 001 Sep 26, 1985 Mar DISC
 >A> @ 2MG A070226 001 Sep 26, 1985 Mar DISC

DICLOFENAC POTASSIUM

FOR SOLUTION;ORAL
 CAMBIA
 + DEPOMED INC 50MG N022165 001 Jun 17, 2009 Jan CAHN

DICLOFENAC SODIUM

SOLUTION;TOPICAL
 PENNSAID
 + MALLINCKRODT INC 2% N204623 001 Jan 16, 2014 Jan NEWA

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL
 DICLOFENAC SODIUM AND MISOPROSTOL
 >A> AB EAGLE PHARMS 50MG;0.2MG A200540 001 Mar 14, 2014 Mar NEWA
 >A> AB 75MG;0.2MG A200540 002 Mar 14, 2014 Mar NEWA

DIGOXIN

TABLET;ORAL
 LANOXIN
 COVIS PHARMA 0.0625MG N020405 001 Sep 30, 1997 Jan CMFD
 0.1875MG N020405 003 Sep 30, 1997 Jan CMFD

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
 DILTIAZEM HYDROCHLORIDE
 >D> AB4 NESHER PHARMS 120MG A076563 002 Sep 12, 2006 Mar DISC
 >A> @ 120MG A076563 002 Sep 12, 2006 Mar DISC
 >D> AB4 180MG A076563 003 Sep 12, 2006 Mar DISC
 >A> @ 180MG A076563 003 Sep 12, 2006 Mar DISC
 >D> AB4 240MG A076563 004 Sep 12, 2006 Mar DISC
 >A> @ 240MG A076563 004 Sep 12, 2006 Mar DISC

CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HYDROCHLORIDE

>D>	AB4		300MG	A076563	005	Sep 12, 2006	Mar	DISC
>A>	@		300MG	A076563	005	Sep 12, 2006	Mar	DISC
>D>	AB4		360MG	A076563	006	Sep 12, 2006	Mar	DISC
>A>	@		360MG	A076563	006	Sep 12, 2006	Mar	DISC
>D>	AB4		420MG	A076563	001	Sep 12, 2006	Mar	DISC
>A>	@		420MG	A076563	001	Sep 12, 2006	Mar	DISC

INJECTABLE; INJECTION
DILTIAZEM HYDROCHLORIDE
@ AGILA SPECLTS 5MG/ML

A075375	001	Sep 30, 1999	Feb	CAHN
---------	-----	--------------	-----	------

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

>D>	AB	GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991	Mar	DISC
>A>	@		25MG	A088999	001	Feb 05, 1991	Mar	DISC
>D>	AB		50MG	A089000	001	Feb 05, 1991	Mar	DISC
>A>	@		50MG	A089000	001	Feb 05, 1991	Mar	DISC
>D>	AB		75MG	A089001	001	Feb 05, 1991	Mar	DISC
>A>	@		75MG	A089001	001	Feb 05, 1991	Mar	DISC

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB	ROXANE	250MG	A202652	001	Feb 05, 2014	Jan	NEWA
AB		500MG	A202652	002	Feb 05, 2014	Jan	NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

>A>		PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Mar	NEWA
>A>			80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Mar	NEWA
>A>			130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Mar	NEWA
>A>			200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Mar	NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	MACLEODS PHARMS LTD	23MG	A202631	001	Jan 22, 2014	Jan	NEWA
----	---------------------	------	---------	-----	--------------	-----	------

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP	SANDOZ	4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan	NEWA
----	--------	--------------------	---------	-----	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995	Feb	CAHN
AP		10MG/VIAL	A063097	001	May 21, 1990	Feb	CAHN
AP		20MG/VIAL	A063097	002	May 21, 1990	Feb	CAHN
AP		50MG/VIAL	A063097	003	May 21, 1990	Feb	CAHN
AP		200MG/100ML	A063336	004	Feb 28, 1995	Feb	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	LUPIN LTD	EQ 50MG BASE	A204234	001	Mar 05, 2014	Feb	NEWA
AB		EQ 75MG BASE	A204234	002	Mar 05, 2014	Feb	NEWA
AB		EQ 100MG BASE	A204234	003	Mar 05, 2014	Feb	NEWA

DOXYCYCLINE HYCLATE

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	CRLD
+		EQ 200MG BASE	N050795	005	Apr 11, 2013	Feb	CRLD

DROXIDOPACAPSULE;ORAL
NORTHERA

	CHELSEA THERAPS INC	100MG	N203202	001	Feb 18, 2014	Feb NEWA
		200MG	N203202	002	Feb 18, 2014	Feb NEWA
+		300MG	N203202	003	Feb 18, 2014	Feb NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

	DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE					
AB	ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Feb NEWA
	JALYN					
AB	+ GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb CFTG

ECONAZOLE NITRATEAEROSOL, FOAM;TOPICAL
ECOZA

+	VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Feb CAHN
---	--------------------	----	---------	-----	--------------	----------

CREAM;TOPICAL

SPECTAZOLE

@	MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jan CAHN
---	-----------------	----	---------	-----	--------------	----------

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

EPIRUBICIN HYDROCHLORIDE

>D>	AP	MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Mar DISC
>A>		@	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Mar DISC
>D>	AP		200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Mar DISC
>A>		@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Mar DISC

ERYTHROMYCIN STEARATE

TABLET;ORAL

ERYTHROMYCIN STEARATE

@	ANI PHARMS INC	EQ 250MG BASE	A061461	001		Feb CAHN
@		EQ 250MG BASE	A061591	001		Jan CAHN
@		EQ 500MG BASE	A061461	002		Feb CAHN
@		EQ 500MG BASE	A063179	001	May 15, 1990	Feb CAHN

ESCITALOPRAM OXALATE

TABLET;ORAL

ESCITALOPRAM OXALATE

AB	TEVA PHARMS USA	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb CAHN
AB		EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb CAHN
AB		EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb CAHN

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

>A>		NEXIUM					
>A>		ASTRAZENECA LP	EQ 20MG BASE	N204655	001	Mar 28, 2014	Mar NEWA

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

>A>	AB	DR REDDYS LABS LTD	1MG	A091024	001	Apr 15, 2014	Mar NEWA
>A>	AB		2MG	A091024	002	Apr 15, 2014	Mar NEWA
>A>	AB		3MG	A091024	003	Apr 15, 2014	Mar NEWA
>A>	AB	GLENMARK GENERICS	1MG	A091166	001	Apr 15, 2014	Mar NEWA
>A>	AB		2MG	A091166	002	Apr 15, 2014	Mar NEWA
>A>	AB		3MG	A091166	003	Apr 15, 2014	Mar NEWA
>D>		@ LUPIN LTD	1MG	A091124	001	Sep 13, 2011	Mar CMFD
>A>	AB		1MG	A091124	001	Sep 13, 2011	Mar CMFD
>D>		@	2MG	A091124	002	Sep 13, 2011	Mar CMFD
>A>	AB		2MG	A091124	002	Sep 13, 2011	Mar CMFD
>D>		@	3MG	A091124	003	Sep 13, 2011	Mar CMFD
>A>	AB		3MG	A091124	003	Sep 13, 2011	Mar CMFD
>A>	AB	ROXANE	1MG	A091153	001	Apr 15, 2014	Mar NEWA
>A>	AB		2MG	A091153	002	Apr 15, 2014	Mar NEWA
>A>	AB		3MG	A091153	003	Apr 15, 2014	Mar NEWA
	AB	TEVA	1MG	A091169	001	May 23, 2011	Jan CMFD
	AB		2MG	A091169	002	May 23, 2011	Jan CMFD
	AB		3MG	A091169	003	May 23, 2011	Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	HAUPT PHARMA	0.02MG;0.1MG	A201108	001	Feb 05, 2014	Jan	NEWA
-----	--------------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ORTHO EVRA

>A>	AB	+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar	CFTG
>A>		+		0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar	CPOT
>D>		+		0.75MG;6MG	N021180	001	Nov 20, 2001	Mar	CPOT
>A>			XULANE						
>A>	AB		MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-21

GILDESS 1.5/30

>A>	AB		VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012	Mar	NEWA
			GILDESS 1/20						
>A>	AB		VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Mar	NEWA
			LARIN 1.5/30						
>A>	AB		NOVAST LABS LTD	0.03MG;1.5MG	A202996	001	Mar 20, 2014	Mar	NEWA

ETODOLAC

CAPSULE;ORAL

ETODOLAC

			@ ANI PHARMS INC	200MG	A074899	001	Jul 08, 1997	Feb	CAHN
			@	200MG	A075126	001	Sep 16, 1999	Jan	CAHN
			@	300MG	A074899	002	Jul 08, 1997	Feb	CAHN
AB				300MG	A075126	002	Sep 16, 1999	Jan	CAHN

ETOMIDATE

INJECTABLE;INJECTION

ETOMIDATE

AP	AGILA SPECLTS			2MG/ML	A078289	001	Jan 02, 2009	Feb	CAHN
----	---------------	--	--	--------	---------	-----	--------------	-----	------

ETOPOSIDE

INJECTABLE;INJECTION

ETOPOSIDE

			@ PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996	Feb	CAHN
--	--	--	-------------------	---------	---------	-----	--------------	-----	------

EXENATIDE SYNTHETIC

INJECTABLE;SUBCUTANEOUS

BYETTA

>D>		+	AMYLIN	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar	CAHN
>D>		+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar	CAHN
>A>		+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar	CAHN
>A>		+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar	CAHN

FAMOTIDINE

INJECTABLE;INJECTION

FAMOTIDINE PRESERVATIVE FREE

AP	BEDFORD LABS			10MG/ML	A075825	001	Apr 17, 2001	Feb	CAHN
----	--------------	--	--	---------	---------	-----	--------------	-----	------

FENOFIBRATE

TABLET;ORAL

FENOGLIDE

			SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
		+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN

FLORBETABEN F-18

SOLUTION;INTRAVENOUS

NEURACEQ

>A>		+	PIRAMAL IMAGING	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Mar	NEWA
-----	--	---	-----------------	----------------------	---------	-----	--------------	-----	------

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS		FLUDEOXYGLUCOSE F18					
AP	ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014	Jan	NEWA
AP	LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan	NEWA
	@ WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004	Feb	DISC
AP	WUSM CYCLOTRON	20-300mCi/ML	A203935	001	Feb 05, 2014	Jan	NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL		FLUDROCORTISONE ACETATE					
AB	HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN
AB		0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN
AB		0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN
AB		0.1MG	A091302	001	Jul 22, 2011	Jan	CAHN

FLUNISOLIDE

AEROSOL, METERED; INHALATION		AEROSPAN HFA					
>D>	+ ACTON PHARMS	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Mar	CAHN
>A>	+ MEDA PHARMS INC	EQ 78MG BASE/INH	N021247	001	Jan 27, 2006	Mar	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL		FLUOXETINE HYDROCHLORIDE					
AB2	ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Jan	CAHN
AB2		EQ 20MG BASE	A076287	002	May 20, 2008	Jan	CAHN
TABLET; ORAL		SARAFEM					
AB1	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860	001	May 19, 2006	Jan	CFTG
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan	CFTG
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan	CFTG
SELFEMRA							
AB1	TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Jan	NEWA
AB1		EQ 15MG BASE	A200151	002	Feb 03, 2014	Jan	NEWA
AB1		EQ 20MG BASE	A200151	003	Feb 03, 2014	Jan	NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR; ORAL		FLUPHENAZINE HYDROCHLORIDE					
	@ ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993	Feb	CAHN

FOLIC ACID

TABLET; ORAL		FOLIC ACID					
AA	CADILA PHARMS LTD	1 MG	A202437	001	Jan 27, 2014	Jan	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL		FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE					
AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb	CAIN
AB	+	20MG;12.5MG	A079025	002	Sep 17, 2010	Feb	CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL		FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE						
AB	+	EMCURE PHARMS INDIA	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan	CRLD

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION		CEREBYX					
AP	PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb	CMFD
FOSPHENYTOIN SODIUM							
AP	AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb	CAHN

FUROSEMIDEINJECTABLE; INJECTION
FUROSEMIDE

AP CLARIS LIFESCIENCES 10MG/ML A202747 001 Jan 27, 2014 Jan NEWA

TABLET; ORAL
FUROSEMIDE

>A>	AB	CARACO	20MG	A091258	001	Apr 01, 2014	Mar	NEWA
>A>	AB		40MG	A091258	002	Apr 01, 2014	Mar	NEWA
>A>	AB		80MG	A091258	003	Apr 01, 2014	Mar	NEWA

GABAPENTINTABLET; ORAL
GABAPENTIN

AB	ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb	CAHN
AB		800MG	A203244	001	Jul 12, 2013	Feb	CAHN

GLATIRAMER ACETATEINJECTABLE; SUBCUTANEOUS
COPAXONE

+ TEVA PHARMS USA 40MG/ML N020622 003 Jan 28, 2014 Jan NEWA

GLYCOPYRROLATETABLET; ORAL
GLYCOPYRROLATE

AA	STASON PHARMS	1MG	A091182	001	Feb 03, 2014	Jan	NEWA
AA		2MG	A091182	002	Feb 03, 2014	Jan	NEWA
AA	VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Feb	CAHN
AA		2MG	A090020	002	Oct 19, 2011	Feb	CAHN

GUANABENZ ACETATETABLET; ORAL
GUANABENZ ACETATE

	ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995	Jan	CAHN
>A>	@	EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar	CAHN
	+	EQ 8MG BASE	A074149	002	Apr 07, 1995	Jan	CAHN
>A>	@	EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar	CAHN
>D>	@ TEVA PHARMS	EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar	CAHN
>D>	@	EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar	CAHN

HALOPERIDOL DECANOATEINJECTABLE; INJECTION
HALOPERIDOL DECANOATE

AO	AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb	CMFD
AO		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb	CMFD

HEPARIN SODIUMINJECTABLE; INJECTION
HEPARIN SODIUM

>A>	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011	Mar	NEWA	
>D>	AP	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar	CRLD	
>A>	+		5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar	CRLD	
>D>		PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar	CRLD	
>A>	+		1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar	CRLD	
>D>			5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar	CRLD	
>A>	+		5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar	CRLD	
>D>			10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar	CRLD	
>A>	+		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar	CRLD	
		HEPARIN SODIUM IN PLASTIC CONTAINER							
>D>	AP	+	FRESENIUS KABI USA	1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar	CTEC
>A>		+		1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar	CTEC
>D>	AP	+		10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar	CTEC
>A>		+		10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar	CTEC
>D>	AP	+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar	CTEC
>A>		+		20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar	CTEC
		HEPARIN SODIUM PRESERVATIVE FREE							
>A>		+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar	NEWA
>D>	AP	+	HOSPIRA	10,000 UNITS/ML	A089522	001	May 04, 1987	Mar	CTEC
>A>		+		10,000 UNITS/ML	A089522	001	May 04, 1987	Mar	CTEC
>D>			PFIZER	1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar	CRLD
>A>		+		1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar	CRLD

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

>A>	AB	CARACO	12.5MG	A090651	001	Apr 07, 2014	Mar	NEWA
-----	----	--------	--------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

>A>		MYLAN	15MG;250MG	A070265	002	Jan 23, 1986	Mar	CMS1
-----	--	-------	------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB		INDICUS PHARMA	12.5MG;7.5MG	A202150	001	Mar 07, 2014	Feb	NEWA
AB			12.5MG;15MG	A202150	002	Mar 07, 2014	Feb	NEWA
AB			25MG;15MG	A202150	003	Mar 07, 2014	Feb	NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>A>	AB	MYLAN	25MG;40MG	A070947	002	Mar 04, 1987	Mar	CMS1
-----	----	-------	-----------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

AB		BOEHRINGER INGELHEIM	12.5MG;40MG	N021162	001	Nov 17, 2000	Feb	CFTG
AB			12.5MG;80MG	N021162	002	Nov 17, 2000	Feb	CFTG
AB	+		25MG;80MG	N021162	003	Apr 19, 2004	Feb	CFTG

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB		ALEMBIC PHARMS LTD	12.5MG;40MG	A203010	001	Feb 25, 2014	Feb	NEWA
AB			12.5MG;80MG	A203010	002	Feb 25, 2014	Feb	NEWA
AB			25MG;80MG	A203010	003	Feb 25, 2014	Feb	NEWA
AB		MYLAN PHARMS INC	12.5MG;40MG	A091648	001	Feb 25, 2014	Feb	NEWA
AB			12.5MG;80MG	A091648	002	Feb 25, 2014	Feb	NEWA
AB			25MG;80MG	A091648	003	Feb 25, 2014	Feb	NEWA
AB		TORRENT PHARMS LTD	12.5MG;40MG	A201192	001	Feb 25, 2014	Feb	NEWA
AB			12.5MG;80MG	A201192	002	Feb 25, 2014	Feb	NEWA
AB			25MG;80MG	A201192	003	Feb 25, 2014	Feb	NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

>D>	AT	TARO	1%	A086155	001		Mar	DISC
>A>		@	1%	A086155	001		Mar	DISC

LOTION; TOPICAL

ALA-CORT

>D>	AT	CROWN LABS	1%	A083201	001		Mar	DISC
>A>		@	1%	A083201	001		Mar	DISC

NUTRACORT

>D>	AT	DOW PHARM	1%	A080443	003		Mar	DISC
>A>		@	1%	A080443	003		Mar	DISC

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED; TOPICAL

HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%

@	VINTAGE PHARMS	1%;1%	A089440	001	May 17, 1988	Feb	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

BONIVA

AP	+	ROCHE	EQ 3MG BASE/3ML	N021858	001	Jan 06, 2006	Feb	CFTG
----	---	-------	-----------------	---------	-----	--------------	-----	------

IBANDRONATE SODIUM

AP		SUN PHARM INDS LTD	EQ 3MG BASE/3ML	A090853	001	Feb 14, 2014	Feb	NEWA
----	--	--------------------	-----------------	---------	-----	--------------	-----	------

INDOMETHACIN

CAPSULE; ORAL

TIVORBEX

IROKO PHARMS LLC

			20MG	N204768	001	Feb 24, 2014	Feb	NEWA
--	--	--	------	---------	-----	--------------	-----	------

+

			40MG	N204768	002	Feb 24, 2014	Feb	NEWA
--	--	--	------	---------	-----	--------------	-----	------

		CAPSULE, EXTENDED RELEASE;ORAL							
		INDOMETHACIN							
>A>	AB	MYLAN PHARMS INC	75MG	A202139	001	Mar 20, 2014	Mar	NEWA	
		<u>INSULIN ASPART RECOMBINANT</u>							
		INJECTABLE;SUBCUTANEOUS							
		NOVOLOG FLEXTOUCH							
	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Feb	NEWA	
		<u>INSULIN DETEMIR RECOMBINANT</u>							
		INJECTABLE;SUBCUTANEOUS							
		LEVEMIR FLEXTOUCH							
	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013	Feb	NEWA	
		<u>IPRATROPIUM BROMIDE</u>							
		SOLUTION;INHALATION							
		IPRATROPIUM BROMIDE							
>D>	AN	+	DEY	A074755	001	Jan 10, 1997	Mar	CAHN	
>A>	AN	+	MYLAN SPECLT	A074755	001	Jan 10, 1997	Mar	CAHN	
		<u>ISOFLURANE</u>							
		LIQUID;INHALATION							
		ISOFLURANE							
AN		PIRAMAL ENT	99.9%	A074502	001	Jun 27, 1995	Feb	CAHN	
		<u>ISOSORBIDE MONONITRATE</u>							
		TABLET;ORAL							
		ISOSORBIDE MONONITRATE							
AB		ANI PHARMS INC	20MG	A075147	001	Nov 27, 1998	Jan	CAHN	
		<u>ISRADIPINE</u>							
		CAPSULE;ORAL							
		ISRADIPINE							
		@	MIKAH PHARMA	A077169	001	Apr 24, 2006	Feb	DISC	
		@		A077169	002	Apr 24, 2006	Feb	DISC	
			WATSON LABS	A077317	001	Jan 05, 2006	Feb	CTEC	
		+		A077317	002	Jan 05, 2006	Feb	CTEC	
			5MG						
		<u>KETOCONAZOLE</u>							
		TABLET;ORAL							
		NIZORAL							
>A>	AB	+	JANSSEN PHARMS	N018533	001		Mar	CAHN	
>D>	AB	+	ORTHO MCNEIL JANSSEN	N018533	001		Mar	CAHN	
		<u>KETOROLAC TROMETHAMINE</u>							
		SOLUTION/DROPS;OPHTHALMIC							
		ACUVAIL							
AT		+	ALLERGAN	N022427	001	Jul 22, 2009	Jan	CFTG	
			KETOROLAC TROMETHAMINE						
		@	AKORN	A203376	001	Feb 10, 2014	Feb	DISC	
AT				A203376	001	Feb 10, 2014	Jan	NEWA	
			0.45%						
			0.45%						
		<u>LAMIVUDINE; ZIDOVUDINE</u>							
		TABLET;ORAL							
		LAMIVUDINE AND ZIDOVUDINE							
AB		HETERO LABS LTD V	150MG;300MG	A203259	001	Feb 03, 2014	Jan	NEWA	
		<u>LANSOPRAZOLE</u>							
		TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL							
		LANSOPRAZOLE							
		@	ANI PHARMS INC	A078730	001	Oct 15, 2010	Jan	CAHN	
		@		A078730	002	Oct 15, 2010	Jan	CAHN	
			15MG						
			30MG						
		<u>LEVETIRACETAM</u>							
		TABLET;ORAL							
		LEVETIRACETAM							
AB		VINTAGE PHARMS	250MG	A077319	001	Mar 20, 2009	Feb	CAHN	
AB			500MG	A077319	002	Mar 20, 2009	Feb	CAHN	
AB			750MG	A077319	003	Mar 20, 2009	Feb	CAHN	

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

AB	VINTAGE PHARMS	500MG	A201464	001	May 25, 2012	Feb	CAHN
AB		750MG	A201464	002	May 25, 2012	Feb	CAHN

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AA	L PERRIGO CO	2.5MG/5ML	A091263	001	Nov 07, 2011	Jan	CAHN
----	--------------	-----------	---------	-----	--------------	-----	------

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

	+ ROXANE	2MG	A074278	001	Mar 31, 2000	Feb	CRLD
--	----------	-----	---------	-----	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

>A>	AP	AGILA SPECLTS	2%	A202242	001	Apr 11, 2014	Mar	NEWA
-----	----	---------------	----	---------	-----	--------------	-----	------

>D>		LIDOPEN						
-----	--	---------	--	--	--	--	--	--

>D>	AP	MERIDIAN MEDCL TECHN	10%	N017549	001		Mar	DISC
-----	----	----------------------	-----	---------	-----	--	-----	------

>A>		@	10%	N017549	001		Mar	DISC
-----	--	---	-----	---------	-----	--	-----	------

XYLOCAINE PRESERVATIVE FREE

>D>	AP	+ FRESENIUS KABI USA	10%	N016801	003		Mar	CTEC
-----	----	----------------------	-----	---------	-----	--	-----	------

>A>		+	10%	N016801	003		Mar	CTEC
-----	--	---	-----	---------	-----	--	-----	------

JELLY;TOPICAL

ANESTACON

@	DSM PHARMS INC	2%	A080429	001		Jan	CAHN
---	----------------	----	---------	-----	--	-----	------

SOLUTION;TOPICAL

LIDOCAINE HYDROCHLORIDE

AT	IGI LABS INC	4%	A204494	001	Mar 12, 2014	Feb	NEWA
----	--------------	----	---------	-----	--------------	-----	------

SYSTEM;INTRADERMAL

ZINGO

>D>		@ POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Mar	CMFD
-----	--	-----------------	-------	---------	-----	--------------	-----	------

>A>			0.5MG	N022114	001	Aug 16, 2007	Mar	CMFD
-----	--	--	-------	---------	-----	--------------	-----	------

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX

	+ BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Feb	CAHN
--	-----------------------	------	---------	-----	--------------	-----	------

LULICONAZOLE

CREAM;TOPICAL

LUZU

	+ MEDICIS	1%	N204153	001	Nov 14, 2013	Jan	CRLD
--	-----------	----	---------	-----	--------------	-----	------

MALATHION

LOTION;TOPICAL

MALATHION

>D>	AT	MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009	Mar	DISC
-----	----	------------------	------	---------	-----	--------------	-----	------

>A>		@	0.5%	A078743	001	Mar 06, 2009	Mar	DISC
-----	--	---	------	---------	-----	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

TABLET;ORAL

MEDROXYPROGESTERONE ACETATE

>D>	BP	USL PHARMA	10MG	A088484	001	Jul 26, 1984	Mar	DISC
-----	----	------------	------	---------	-----	--------------	-----	------

>A>		@	10MG	A088484	001	Jul 26, 1984	Mar	DISC
-----	--	---	------	---------	-----	--------------	-----	------

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

>D>	AP	INTL MEDICATION	10MG/ML	A081309	001	Aug 30, 1993	Mar	DISC
-----	----	-----------------	---------	---------	-----	--------------	-----	------

>A>		@	10MG/ML	A081309	001	Aug 30, 1993	Mar	DISC
-----	--	---	---------	---------	-----	--------------	-----	------

METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GLUMETZA

>D>		+ SALIX PHARMS INC	1GM	N021748	002	Jun 03, 2005	Mar	CAHN
-----	--	--------------------	-----	---------	-----	--------------	-----	------

		+	1GM	N021748	002	Jun 03, 2005	Feb	CTEC
--	--	---	-----	---------	-----	--------------	-----	------

>D>			500MG	N021748	001	Jun 03, 2005	Mar	CAHN
-----	--	--	-------	---------	-----	--------------	-----	------

			500MG	N021748	001	Jun 03, 2005	Feb	CTEC
--	--	--	-------	---------	-----	--------------	-----	------

	TABLET, EXTENDED RELEASE;ORAL						
	GLUMETZA						
>A>	+	SANTARUS INC	1GM	N021748	002	Jun 03, 2005	Mar CAHN
>A>			500MG	N021748	001	Jun 03, 2005	Mar CAHN
	<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE						
AB		TEVA PHARMS USA	500MG;EQ 15MG BASE	A091155	001	Mar 10, 2014	Feb NEWA
AB			850MG;EQ 15MG BASE	A091155	002	Mar 10, 2014	Feb NEWA
	<u>METHAZOLAMIDE</u>						
	TABLET;ORAL						
	METHAZOLAMIDE						
AB		ANI PHARMS INC	25MG	A040001	001	Jun 30, 1993	Jan CAHN
AB			50MG	A040001	002	Jun 30, 1993	Jan CAHN
	<u>METHIMAZOLE</u>						
	TABLET;ORAL						
	METHIMAZOLE						
AB		VINTAGE PHARMS	5MG	A202068	001	Mar 07, 2012	Feb CAHN
AB			10MG	A202068	002	Mar 07, 2012	Feb CAHN
	<u>METHSCOPOLAMINE BROMIDE</u>						
	TABLET;ORAL						
	METHSCOPOLAMINE BROMIDE						
AA		VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb CAHN
AA			5MG	A040624	002	Dec 28, 2006	Feb CAHN
	<u>METHYLERGONOVINE MALEATE</u>						
	INJECTABLE;INJECTION						
	METHERGINE						
AP	+	EDISON THERAPS LLC	0.2MG/ML	N006035	004		Feb CAHN
	TABLET;ORAL						
	METHERGINE						
AB	+	EDISON THERAPS LLC	0.2MG	N006035	003		Feb CAHN
	<u>METHYLPHENIDATE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	METHYLPHENIDATE HYDROCHLORIDE						
AB		COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb NEWA
AB			10MG	A091159	002	Mar 12, 2014	Feb NEWA
AB			20MG	A091159	003	Mar 12, 2014	Feb NEWA
	<u>METRONIDAZOLE</u>						
	GEL;VAGINAL						
	METRONIDAZOLE						
>A>		VALEANT PHARM NORTH	1.3%	N205223	001	Mar 24, 2014	Mar NEWA
	TABLET;ORAL						
	METRONIDAZOLE						
>D>	AB	TEVA	500MG	A070044	001	Feb 08, 1985	Mar CAHN
	AB	UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014	Jan NEWA
	AB		500MG	A203458	002	Jan 22, 2014	Jan NEWA
>A>	AB	WATSON LABS INC	500MG	A070044	001	Feb 08, 1985	Mar CAHN
	<u>MILTEFOSINE</u>						
	CAPSULE;ORAL						
	IMPAVIDO						
>A>		PALADIN THERAP	50MG	N204684	001	Mar 19, 2014	Mar NEWA
	<u>MIVACURIUM CHLORIDE</u>						
	INJECTABLE;INJECTION						
	MIVACURIUM CHLORIDE						
	@	AGILA SPECLTS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	Feb CAHN
	<u>MODAFINIL</u>						
	TABLET;ORAL						
	MODAFINIL						
AB		APOTEX INC	100MG	A077667	001	Feb 03, 2014	Jan NEWA
AB			200MG	A077667	002	Feb 03, 2014	Jan NEWA

MOMETASONE FUROATEPOWDER; INHALATION
ASMANEX TWISTHALER

>A>		MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008	Mar CAHN
>A>	+		0.22MG/INH	N021067	001	Mar 30, 2005	Mar CAHN
>D>		SCHERING	0.11MG/INH	N021067	002	Feb 01, 2008	Mar CAHN
>D>	+		0.22MG/INH	N021067	001	Mar 30, 2005	Mar CAHN

MORPHINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
AVINZA

>D>	AB2	KING PFIZER	30MG	N021260	001	Mar 20, 2002	Mar CAHN
>D>	AB2		45MG	N021260	005	Dec 18, 2008	Mar CAHN
>D>	AB2		60MG	N021260	002	Mar 20, 2002	Mar CAHN
>D>	AB2		75MG	N021260	006	Dec 18, 2008	Mar CAHN
>D>	AB2		90MG	N021260	003	Mar 20, 2002	Mar CAHN
>D>	AB2	+	120MG	N021260	004	Mar 20, 2002	Mar CAHN
>A>	AB2	KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002	Mar CAHN
>A>	AB2		45MG	N021260	005	Dec 18, 2008	Mar CAHN
>A>	AB2		60MG	N021260	002	Mar 20, 2002	Mar CAHN
>A>	AB2		75MG	N021260	006	Dec 18, 2008	Mar CAHN
>A>	AB2		90MG	N021260	003	Mar 20, 2002	Mar CAHN
>A>	AB2	+	120MG	N021260	004	Mar 20, 2002	Mar CAHN

SOLUTION; ORAL

MORPHINE SULFATE

AA		CARACO	10MG/5ML	A201011	001	Feb 05, 2014	Jan NEWA
AA			20MG/5ML	A201011	002	Feb 05, 2014	Jan NEWA

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL
EMBEDA

>D>		ALPHARMA KING	20MG; 0.8MG	N022321	001	Aug 13, 2009	Mar CAHN
>D>			30MG; 1.2MG	N022321	002	Aug 13, 2009	Mar CAHN
>D>			50MG; 2MG	N022321	003	Aug 13, 2009	Mar CAHN
>D>	+		60MG; 2.4MG	N022321	004	Aug 13, 2009	Mar CAHN
>D>			80MG; 3.2MG	N022321	005	Aug 13, 2009	Mar CAHN
>D>			100MG; 4MG	N022321	006	Aug 13, 2009	Mar CAHN
>A>		ALPHARMA PHARMS	20MG; 0.8MG	N022321	001	Aug 13, 2009	Mar CAHN
>A>			30MG; 1.2MG	N022321	002	Aug 13, 2009	Mar CAHN
>A>			50MG; 2MG	N022321	003	Aug 13, 2009	Mar CAHN
>A>	+		60MG; 2.4MG	N022321	004	Aug 13, 2009	Mar CAHN
>A>			80MG; 3.2MG	N022321	005	Aug 13, 2009	Mar CAHN
>A>			100MG; 4MG	N022321	006	Aug 13, 2009	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDE

TABLET; ORAL

AVELOX

AB	+	BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Feb CFTG
		MOXIFLOXACIN HYDROCHLORIDE					
AB		AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014	Feb NEWA
AB		DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Feb NEWA
AB		TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014	Feb NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 400MG BASE	A200160	001	Apr 03, 2014	Mar NEWA

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

>A>	AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Mar NEWA
>A>	AP		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Mar NEWA
	AP	ANTIBIOTICE	EQ 1GM BASE/VIAL	A090560	001	Oct 03, 2011	Jan CPOT
	AP		EQ 2GM BASE/VIAL	A090560	002	Oct 03, 2011	Jan CPOT
	AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Feb CAHN
	AP		EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Feb CAHN
	AP		EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Feb CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HYDROCHLORIDE

AP		MYLAN INSTITUTIONAL	0.4MG/ML	A204997	001	Mar 06, 2014	Feb NEWA
----	--	---------------------	----------	---------	-----	--------------	----------

NAPROXEN

TABLET; ORAL

NAPROXEN

@	DAVA PHARMS INC	250MG	A074410	001	Apr 28, 1995	Feb	DISC
@		375MG	A074410	002	Apr 28, 1995	Feb	DISC
@		500MG	A074410	003	Apr 28, 1995	Feb	DISC

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Jan	CAIN
AB		EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Jan	CAIN
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan	CAIN

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

AB	STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Jan	CAHN
----	---------------------	-------	---------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

>A>	AB	APOTEX INC	400MG	A205258	001	Apr 03, 2014	Mar	NEWA
>A>	AB	SANDOZ	400MG	A203411	001	Apr 03, 2014	Mar	NEWA
		VIRAMUNE XR						
>D>	+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar	CFTG
>A>	AB	+	400MG	N201152	001	Mar 25, 2011	Mar	CFTG

NIACIN

TABLET, EXTENDED RELEASE; ORAL

NIACIN

>A>	AB	LUPIN LTD	1GM	A090446	001	Mar 20, 2014	Mar	NEWA
>A>	AB		500MG	A090860	001	Mar 20, 2014	Mar	NEWA
>A>	AB		750MG	A090892	001	Mar 20, 2014	Mar	NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE; ORAL

NICARDIPINE HYDROCHLORIDE

AB	ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan	CAHN
AB		20MG	A074540	001	Oct 28, 1996	Jan	CAHN
AB		30MG	A074439	002	Dec 10, 1996	Jan	CAHN
AB		30MG	A074540	002	Oct 28, 1996	Jan	CAHN

INJECTABLE; INJECTION

NICARDIPINE HYDROCHLORIDE

AP	LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan	CAHN
----	----------	----------------------	---------	-----	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

>A>	AB2	TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar	NEWA
>A>	AB2		60MG	A203126	002	Apr 03, 2014	Mar	NEWA
>A>	AB2		90MG	A203126	003	Apr 03, 2014	Mar	NEWA

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

>A>	AB	THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014	Mar	NEWA
-----	----	----------------------	------	---------	-----	--------------	-----	------

NIZATIDINE

CAPSULE; ORAL

NIZATIDINE

@	ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002	Jan	CAHN
AB		150MG	A075668	001	Sep 12, 2002	Jan	CAHN
@		300MG	A075461	002	Jul 08, 2002	Jan	CAHN
AB		300MG	A075668	002	Sep 12, 2002	Jan	CAHN

OMEGA-3-ACID ETHYL ESTERS

CAPSULE; ORAL

LOVAZA

>D>	+	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar	CFTG
>A>	AB	+	1GM CONTAINS AT LEAST 900MG OF THE	N021654	001	Nov 10, 2004	Mar	CFTG

CAPSULE;ORAL
LOVAZA

ETHYL ESTERS OF OMEGA-3 FATTY
ACIDS

>A> OMEGA-3-ACID ETHYL ESTERS

>A> AB	TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar	NEWA
--------	-----------------	--	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL
ZEGERID

AB	SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb	CAHN
AB	+	40MG;1.1GM	N021849	002	Feb 27, 2006	Feb	CAHN

FOR SUSPENSION;ORAL
ZEGERID

AB	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb	CAHN
AB	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

@	LANNETT	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010	Jan	DISC
---	---------	----------------	---------	-----	--------------	-----	------

TABLET;ORAL
ONDANSETRON HYDROCHLORIDE

AB	IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	Jan	NEWA
AB		EQ 8MG BASE	A203761	002	Jan 23, 2014	Jan	NEWA

OXACILLIN SODIUM

INJECTABLE;INJECTION
OXACILLIN SODIUM

@	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995	Feb	CAHN
@		EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995	Feb	CAHN
@		EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995	Feb	CAHN
@		EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995	Feb	CAHN
@		EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995	Feb	CAHN

OXALIPLATIN

INJECTABLE;IV (INFUSION)
OXALIPLATIN

>A> AP	SUN PHARMA GLOBAL	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Mar	NEWA
>A> AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Mar	NEWA

OXANDROLONE

TABLET;ORAL
OXANDRIN

AB	CREALTA PHARMS LLC	2.5MG	N013718	001		Jan	CAHN
AB	+	10MG	N013718	002	Nov 05, 2001	Jan	CAHN

OXCARBAZEPINE

TABLET;ORAL
OXCARBAZEPINE

@	ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jan	CAHN
@		300MG	A078005	002	Dec 11, 2007	Jan	CAHN
@		600MG	A078005	003	Dec 11, 2007	Jan	CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL
OXYBUTYNIN

AB	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014	Feb	NEWA
AB	+	WATSON LABS (UTAH)	N021351	002	Feb 26, 2003	Feb	CFTG

OXYTOCIN

SOLUTION;NASAL
SYNTOCINON

@	RETROPHIN INC	40USP UNITS/ML	N012285	001		Feb	CAHN
---	---------------	----------------	---------	-----	--	-----	------

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
 PAMIDRONATE DISODIUM
 @ MN PHARMS 30MG/VIAL
 @ 90MG/VIAL

A078300 001 Mar 10, 2009 Jan DISC
 A078300 002 Mar 10, 2009 Jan DISC

PANCRELIPASE (AMYLASE; LIPASE; PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL
 ZENPEP

>A> APTALIS PHARMA US 218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS N022210 007 Mar 25, 2014 Mar NEWA

TABLET; ORAL
 VIOKACE

>D> APTALIS PHARMA US 39,150USP UNITS; 10,440USP UNITS; 39,150USP UNITS N022542 001 Mar 01, 2012 Mar CAHN

>D> + 78,300USP UNITS; 20,880USP UNITS; 78,300USP UNITS N022542 002 Mar 01, 2012 Mar CAHN

>A> FOREST RES INST INC 39,150USP UNITS; 10,440USP UNITS; 39,150USP UNITS N022542 001 Mar 01, 2012 Mar CAHN

>A> + 78,300USP UNITS; 20,880USP UNITS; 78,300USP UNITS N022542 002 Mar 01, 2012 Mar CAHN

PARICALCITOL

CAPSULE; ORAL
 PARICALCITOL

>A> AB BANNER PHARMACAPS 1MCG A202539 001 Mar 27, 2014 Mar NEWA

>A> AB 2MCG A202539 002 Mar 27, 2014 Mar NEWA

>A> AB 4MCG A202539 003 Mar 27, 2014 Mar NEWA

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL
 PAXIL

@ APOTEX TECHNOLOGIES EQ 10MG BASE N020885 001 Oct 09, 1998 Feb CAHN
 @ EQ 20MG BASE N020885 002 Oct 09, 1998 Feb CAHN
 @ EQ 30MG BASE N020885 003 Oct 09, 1998 Feb CAHN
 @ EQ 40MG BASE N020885 004 Oct 09, 1998 Feb CAHN

SUSPENSION; ORAL
 PAXIL

AB + APOTEX TECHNOLOGIES EQ 10MG BASE/5ML N020710 001 Jun 25, 1997 Feb CAHN

TABLET; ORAL
 PAXIL

AB APOTEX TECHNOLOGIES EQ 10MG BASE N020031 001 Dec 29, 1992 Jan CAHN

AB EQ 20MG BASE N020031 002 Dec 29, 1992 Jan CAHN

AB EQ 30MG BASE N020031 003 Dec 29, 1992 Jan CAHN

AB + EQ 40MG BASE N020031 005 Dec 29, 1992 Jan CAHN

@ EQ 50MG BASE N020031 004 Dec 29, 1992 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL
 PAXIL CR

AB APOTEX TECHNOLOGIES EQ 12.5MG BASE N020936 001 Feb 16, 1999 Feb CAHN

AB EQ 25MG BASE N020936 002 Feb 16, 1999 Feb CAHN

AB + EQ 37.5MG BASE N020936 003 Dec 06, 2000 Feb CAHN

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION
 PENICILLIN G POTASSIUM

AP ISTITUTO BIO ITA SPA 5,000,000 UNITS/VIAL A065448 001 Aug 18, 2009 Feb CAHN

AP 20,000,000 UNITS/VIAL A065448 002 Aug 18, 2009 Feb CAHN

PERINDOPRIL ERBUMINE

TABLET; ORAL
 PERINDOPRIL ERBUMINE

AB ANI PHARMS INC 2MG A078138 001 Nov 10, 2009 Jan CAHN

AB 4MG A078138 002 Nov 10, 2009 Jan CAHN

AB 8MG A078138 003 Nov 10, 2009 Jan CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
 PHENTERMINE HYDROCHLORIDE

AA INVAGEN PHARMS 15MG A202858 001 Feb 14, 2014 Feb NEWA

AA 30MG A202858 002 Feb 14, 2014 Feb NEWA

AA 37.5MG A202846 001 Feb 05, 2014 Jan NEWA

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE
AA INVAGEN PHARMS 37.5MG A202942 001 Feb 05, 2014 Jan NEWA

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

@ ANI PHARMS INC 100MG EXTENDED A089441 001 Dec 18, 1986 Jan CAHN

PROMPT PHENYTOIN SODIUM

@ ANI PHARMS INC 100MG PROMPT A080259 001 Jan CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

AB MUTUAL PHARM 5MG A074063 001 Jan 27, 1994 Feb CMFD

AB 10MG A074063 002 Jan 27, 1994 Feb CMFD

AB MYLAN PHARMS INC 5MG A074019 001 Sep 03, 1992 Feb CTEC

AB + 10MG A074019 002 Sep 03, 1992 Feb CTEC

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

PIOGLITAZONE HYDROCHLORIDE

>A> AB LUPIN LTD EQ 15MG BASE A204133 001 Apr 07, 2014 Mar NEWA

>A> AB EQ 30MG BASE A204133 002 Apr 07, 2014 Mar NEWA

>A> AB EQ 45MG BASE A204133 003 Apr 07, 2014 Mar NEWA

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

+ ISTITUTO BIO ITA SPA EQ 2GM BASE/VIAL A065114 001 Nov 14, 2003 Feb CAHN

+ EQ 3GM BASE/VIAL A065114 002 Nov 14, 2003 Feb CAHN

+ EQ 4GM BASE/VIAL A065114 003 Nov 14, 2003 Feb CAHN

+ EQ 40GM BASE/VIAL A065157 001 Jul 12, 2004 Feb CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

AP ISTITUTO BIO ITA SPA EQ 2GM BASE/VIAL;EQ 250MG A065523 001 May 31, 2011 Feb CAHN
BASE/VIAL

AP EQ 3GM BASE/VIAL;EQ 375MG A065523 002 May 31, 2011 Feb CAHN
BASE/VIAL

AP EQ 4GM BASE/VIAL;EQ 500MG A065523 003 May 31, 2011 Feb CAHN
BASE/VIAL

AP EQ 36GM BASE/VIAL;EQ 4.5GM A090498 001 May 31, 2011 Feb CAHN
BASE/VIAL

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION;ORAL

CO-LAV

@ VINTAGE PHARMS 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5. A073428 001 Jan 28, 1992 Feb CAHN
84GM/BOT;22.72GM/BOT

GO-EVAC

@ VINTAGE PHARMS 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5. A073433 001 Apr 28, 1992 Feb CAHN
86GM/BOT;22.74GM/BOT

POSACONAZOLE

>A> SOLUTION;IV (INFUSION)

>A> NOXAFIL

>A> + MERCK SHARP DOHME 300MG/16.7ML (18MG/ML) N205596 001 Mar 13, 2014 Mar NEWA

POTASSIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE

>D> AP INTL MEDICATION 2MEQ/ML A083163 001 Mar DISC

>A> @ 2MEQ/ML A083163 001 Mar DISC

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

MIRAPEX ER

AB + BOEHRINGER INGELHEIM 0.375MG N022421 001 Feb 19, 2010 Jan CFTG

AB 0.75MG N022421 002 Feb 19, 2010 Jan CFTG

AB 1.5MG N022421 003 Feb 19, 2010 Jan CFTG

TABLET, EXTENDED RELEASE;ORAL
MIRAPEX ER

AB		2.25MG	N022421	006	Jun 17, 2011	Jan CFTG
AB		3MG	N022421	004	Feb 19, 2010	Jan CFTG
AB		3.75MG	N022421	007	Jun 17, 2011	Jan CFTG
AB		4.5MG	N022421	005	Feb 19, 2010	Jan CFTG

PRAMIPEXOLE DIHYDROCHLORIDE

AB	ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Jan NEWA
AB		0.75MG	A202206	002	Feb 06, 2014	Jan NEWA
AB		1.5MG	A202206	003	Feb 06, 2014	Jan NEWA
AB		2.25MG	A202206	004	Feb 06, 2014	Jan NEWA
AB		3MG	A202206	005	Feb 06, 2014	Jan NEWA
AB		3.75MG	A202206	006	Feb 06, 2014	Jan NEWA
AB		4.5MG	A202206	007	Feb 06, 2014	Jan NEWA

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS
SYMLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb CAHN
+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb CAHN
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb CAHN

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

	SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE					
AT	+ BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb CRLD
	VASOCIDIN					
	@ NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb DISC

PRIMAQUINE PHOSPHATE

TABLET;ORAL

	PRIMAQUINE					
AB	+ SANOFI AVENTIS US	EQ 15MG BASE	N008316	001		Jan CFTG
	PRIMAQUINE PHOSPHATE					
AB	ALVOGEN INC	EQ 15MG BASE	A203924	001	Feb 03, 2014	Jan NEWA
AB	BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Feb NEWA

PROCAINAMIDE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL
PROCAINAMIDE HYDROCHLORIDE

	@ ANI PHARMS INC	1GM	A040111	001	Dec 13, 1996	Jan CAHN
	@	250MG	A088958	001	Dec 02, 1985	Jan CAHN
	@	500MG	A088959	001	Dec 02, 1985	Jan CAHN
>A>	@	500MG	A088974	001	Jul 22, 1985	Mar CAHN
	@	750MG	A089438	001	Mar 23, 1987	Jan CAHN
>D>	@ COPLEY PHARM	500MG	A088974	001	Jul 22, 1985	Mar CAHN

PROPAFENONE HYDROCHLORIDE

TABLET;ORAL

	PROPAFENONE HYDROCHLORIDE					
AB	ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004	Jan CAHN
AB		225MG	A076550	002	Apr 23, 2004	Jan CAHN
AB		300MG	A076550	003	Apr 23, 2004	Jan CAHN

PROPRANOLOL HYDROCHLORIDE

SOLUTION;ORAL

	HEMANGEOL					
>A>	+ PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014	Mar NEWA

TABLET;ORAL

INDERAL

	@ WYETH PHARMS INC	40MG	N016418	002		Jan DISC
	@	60MG	N016418	009	Oct 18, 1982	Jan DISC
	@	80MG	N016418	004		Jan DISC

PROPRANOLOL HYDROCHLORIDE

	@ ANI PHARMS INC	90MG	A071977	001	Apr 06, 1988	Jan CAHN
--	------------------	------	---------	-----	--------------	----------

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

@ ANI PHARMS INC

50MG

A080215 001

Jan CAHN

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

EVISTA

AB + LILLY 60MG

N020815 001 Dec 09, 1997 Feb CFTG

RALOXIFENE HYDROCHLORIDE

AB TEVA PHARMS USA 60MG

A078193 001 Mar 04, 2014 Feb NEWA

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

>A> AB ACCORD HLTHCARE INC 1.25MG

A202392 001 Apr 15, 2014 Mar NEWA

>A> AB 2.5MG

A202392 002 Apr 15, 2014 Mar NEWA

>A> AB 5MG

A202392 003 Apr 15, 2014 Mar NEWA

>A> AB 10MG

A202392 004 Apr 15, 2014 Mar NEWA

RANITIDINE HYDROCHLORIDE

TABLET, EFFERVESCENT;ORAL

ZANTAC 25

@ GLAXO GRP LTD

EQ 25MG BASE

N020251 003 Apr 01, 2004 Feb DISC

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB ACTAVIS TOTOWA 0.5MG

A090008 001 Jan 22, 2014 Jan NEWA

AB 1MG

A090008 002 Jan 22, 2014 Jan NEWA

AB 2MG

A090008 003 Jan 22, 2014 Jan NEWA

AB AUROBINDO PHARMA LTD 0.5MG

A203820 001 Jan 22, 2014 Jan NEWA

AB 1MG

A203820 002 Jan 22, 2014 Jan NEWA

AB 2MG

A203820 003 Jan 22, 2014 Jan NEWA

AB MYLAN PHARMS INC 1MG

A090252 002 Jan 22, 2014 Jan NEWA

AB 2MG

A090252 003 Jan 22, 2014 Jan NEWA

AB PADDOCK LLC 1MG

A201189 002 Jan 22, 2014 Jan NEWA

AB 2MG

A201189 003 Jan 22, 2014 Jan NEWA

AB SANDOZ 1MG

A078555 002 Jan 22, 2014 Jan NEWA

AB 2MG

A078555 003 Jan 22, 2014 Jan NEWA

RIFABUTIN

CAPSULE;ORAL

MYCOBUTIN

AB + PHARMACIA AND UPJOHN 150MG

N050689 001 Dec 23, 1992 Feb CFTG

RIFABUTIN

AB LUPIN LTD 150MG

A090033 001 Feb 24, 2014 Feb NEWA

RISPERIDONE

SOLUTION;ORAL

RISPERIDONE

AA ANI PHARMS INC 1MG/ML

A076440 001 Jan 30, 2009 Jan CAHN

TABLET;ORAL

RISPERIDONE

AB CARACO 0.25MG

A078036 001 Mar 10, 2014 Feb NEWA

AB 0.5MG

A078036 002 Mar 10, 2014 Feb NEWA

AB 1MG

A078036 003 Mar 10, 2014 Feb NEWA

AB 2MG

A078036 004 Mar 10, 2014 Feb NEWA

AB 3MG

A078036 005 Mar 10, 2014 Feb NEWA

AB 4MG

A078036 006 Mar 10, 2014 Feb NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL

RIZATRIPTAN BENZOATE

AB MACLEODS PHARMS LTD EQ 5MG BASE

A203147 001 Feb 11, 2014 Jan NEWA

AB EQ 10MG BASE

A203147 002 Feb 11, 2014 Jan NEWA

SIMEPREVIR SODIUMCAPSULE;ORAL
OLYSIO

+ JANSSEN RES AND DEV EQ 150MG BASE N205123 001 Nov 22, 2013 Feb CAIN

SODIUM FLUORIDE F-18INJECTABLE;INTRAVENOUS
SODIUM FLUORIDE F-18

>A> AP UCSF RODIOPHARM 10-200mCi/ML A204437 001 Mar 13, 2014 Mar NEWA

SODIUM POLYSTYRENE SULFONATEPOWDER;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

>A> AA EPIC PHARMA LLC 453.6GM/BOT A202333 001 Mar 19, 2014 Mar NEWA

SOLIFENACIN SUCCINATE

TABLET;ORAL

>A> SOLIFENACIN SUCCINATE

>A> AB TEVA PHARMS USA 5MG A091464 001 Apr 02, 2014 Mar NEWA

>A> AB 10MG A091464 002 Apr 02, 2014 Mar NEWA

VESICARE

>D> ASTELLAS 5MG N021518 001 Nov 19, 2004 Mar CFTG

>A> AB 5MG N021518 001 Nov 19, 2004 Mar CFTG

>D> + 10MG N021518 002 Nov 19, 2004 Mar CFTG

>A> AB + 10MG N021518 002 Nov 19, 2004 Mar CFTG

SOMATROPIN RECOMBINANTINJECTABLE;INJECTION
ACCRETROPIN

@ EMERGENT 5MG/ML (5MG/ML)

N021538 001 Jan 23, 2008 Feb CAHN

SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE

AB ORION CORP ORION 25MG A202187 001 Mar 06, 2014 Feb NEWA

AB 50MG A202187 002 Mar 06, 2014 Feb NEWA

AB 100MG A202187 003 Mar 06, 2014 Feb NEWA

SUMATRIPTAN SUCCINATEINJECTABLE;SUBCUTANEOUS
SUMATRIPTAN SUCCINATE

>A> AP AGILA SPECLTS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A203322 001 Apr 14, 2014 Mar NEWA

AB DR REDDYS LABS INC EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090495 001 Jan 29, 2014 Jan NEWA

SUNITINIB MALATE

CAPSULE;ORAL

SUNITINIB MALATE

AB MYLAN PHARMS INC EQ 12.5MG BASE A201275 001 Jan 30, 2014 Jan NEWA

AB EQ 25MG BASE A201275 002 Jan 30, 2014 Jan NEWA

AB EQ 37.5MG BASE A201275 003 Jan 30, 2014 Jan NEWA

AB EQ 50MG BASE A201275 004 Jan 30, 2014 Jan NEWA

SUTENT

AB CPPI CV EQ 12.5MG BASE N021938 001 Jan 26, 2006 Jan CFTG

AB EQ 25MG BASE N021938 002 Jan 26, 2006 Jan CFTG

AB EQ 37.5MG BASE N021938 004 Mar 31, 2009 Jan CFTG

AB + EQ 50MG BASE N021938 003 Jan 26, 2006 Jan CFTG

TASIMELTEONCAPSULE;ORAL
HETLIOZ

+ VANDA PHARMS INC 20MG N205677 001 Jan 31, 2014 Jan NEWA

TEMOZOLOMIDECAPSULE;ORAL
TEMOZOLOMIDE

AB SUN PHARMA GLOBAL 5MG A201742 001 Feb 12, 2014 Feb NEWA

AB 20MG A201742 002 Feb 12, 2014 Feb NEWA

AB 100MG A201742 003 Feb 12, 2014 Feb NEWA

AB 140MG A201742 004 Feb 12, 2014 Feb NEWA

	CAPSULE;ORAL							
	TEMOZOLOMIDE							
AB		180MG	A201742	005	Feb 12, 2014	Feb	NEWA	
AB		250MG	A201742	006	Feb 12, 2014	Feb	NEWA	
>A>	<u>TESTOSTERONE UNDECANOATE</u>							
>A>	INJECTABLE;INTRAMUSCULAR							
>A>	AVEED							
>A>	+	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 04, 2014	Mar	NEWA
	<u>THEOPHYLLINE</u>							
	TABLET, EXTENDED RELEASE;ORAL							
	THEOCHRON							
	@	CARACO	300MG	A087400	002	Jan 11, 1983	Jan	DISC
	<u>THIORIDAZINE HYDROCHLORIDE</u>							
	CONCENTRATE;ORAL							
	THIORIDAZINE HYDROCHLORIDE							
	@	ANI PHARMS INC	100MG/ML	A089603	001	Nov 09, 1987	Feb	CAHN
	TABLET;ORAL							
	THIORIDAZINE HYDROCHLORIDE							
	@	ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983	Feb	CAHN
	@		10MG	A088493	001	May 17, 1985	Feb	CAHN
	@		15MG	A088271	001	Apr 14, 1983	Feb	CAHN
	@		25MG	A088272	001	Apr 14, 1983	Feb	CAHN
	@		50MG	A088194	001	Apr 14, 1983	Feb	CAHN
	@		100MG	A088273	001	Oct 03, 1983	Feb	CAHN
	@		100MG	A088456	001	May 17, 1985	Feb	CAHN
	<u>TOPIRAMATE</u>							
	CAPSULE, DELAYED RELEASE;ORAL							
>A>	QUDEXY XR							
>A>		UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Mar	NEWA
>A>			50MG	N205122	002	Mar 11, 2014	Mar	NEWA
>A>			100MG	N205122	003	Mar 11, 2014	Mar	NEWA
>A>			150MG	N205122	004	Mar 11, 2014	Mar	NEWA
>A>	+		200MG	N205122	005	Mar 11, 2014	Mar	NEWA
	<u>TRAMADOL HYDROCHLORIDE</u>							
	TABLET;ORAL							
	TRAMADOL HYDROCHLORIDE							
>A>	AB	AUROBINDO PHARMA LTD	50MG	A203494	001	Mar 31, 2014	Mar	NEWA
	<u>TRANEXAMIC ACID</u>							
	INJECTABLE;INJECTION							
	TRANEXAMIC ACID							
AP		ACIC FINE CHEMS	100MG/ML	A202436	001	Feb 11, 2014	Jan	NEWA
	TABLET;ORAL							
	TRANEXAMIC ACID							
AB		APOTEX INC	650 MG	A202286	001	Jan 27, 2014	Jan	NEWA
	<u>TRAVOPROST</u>							
	SOLUTION/DROPS;OPHTHALMIC							
	TRAVOPROST							
	+	PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb	CRLD
	<u>TRETINOIN</u>							
	GEL;TOPICAL							
	RETIN-A-MICRO							
	+	VALEANT INTL	0.08%	N020475	003	Jan 28, 2014	Jan	NEWA
	SOLUTION;TOPICAL							
	RETIN-A							
	+	VALEANT INTL	0.05%	N016921	001		Feb	CTEC
	TRETINOIN							
	@	WOCKHARDT	0.05%	A075260	001	Jan 25, 1999	Feb	DISC

TRIAMCINOLONE ACETONIDE

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

>D>	AT	TARO	0.1%	A089129	001	Aug 14, 1986	Mar	DISC
>A>		@	0.1%	A089129	001	Aug 14, 1986	Mar	DISC

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

>A>	AB	APOTEX INC	EQ 1GM BASE	A090500	002	Apr 04, 2014	Mar	NEWA
>A>	AB		EQ 500MG BASE	A090500	001	Apr 04, 2014	Mar	NEWA
	AB	CIPLA LTD	EQ 1GM BASE	A077135	002	May 24, 2010	Jan	CAHN
	AB		EQ 500MG BASE	A077135	001	May 24, 2010	Jan	CAHN

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

AA		ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Jan	CAHN
----	--	----------------	-----------	---------	-----	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

AP		AGILA SPECLTS	EQ 10GM BASE/VIAL	A091554	001	Sep 19, 2011	Feb	CAHN
----	--	---------------	-------------------	---------	-----	--------------	-----	------

WARFARIN SODIUM

INJECTABLE; INJECTION

COUMADIN

>D>								
>D>	+	BRISTOL MYERS SQUIBB	5MG/VIAL	N009218	024	Feb 07, 1995	Mar	DISC
>A>		@	5MG/VIAL	N009218	024	Feb 07, 1995	Mar	DISC

TABLET; ORAL

COUMADIN

>D>								
>D>	AB	BRISTOL MYERS SQUIBB	1MG	N009218	022	Mar 01, 1990	Mar	DISC
>A>		@	1MG	N009218	022	Mar 01, 1990	Mar	DISC
>D>	AB		2MG	N009218	013		Mar	DISC
>A>		@	2MG	N009218	013		Mar	DISC
>D>	AB		2.5MG	N009218	018		Mar	DISC
>A>		@	2.5MG	N009218	018		Mar	DISC
>D>	AB		3MG	N009218	025	Nov 18, 1996	Mar	DISC
>A>		@	3MG	N009218	025	Nov 18, 1996	Mar	DISC
>D>	AB		4MG	N009218	023	Aug 24, 1993	Mar	DISC
>A>		@	4MG	N009218	023	Aug 24, 1993	Mar	DISC
>D>	AB		5MG	N009218	007		Mar	DISC
>A>		@	5MG	N009218	007		Mar	DISC
>D>	AB		6MG	N009218	026	Nov 18, 1996	Mar	DISC
>A>		@	6MG	N009218	026	Nov 18, 1996	Mar	DISC
>D>	AB		7.5MG	N009218	016		Mar	DISC
>A>		@	7.5MG	N009218	016		Mar	DISC
>D>	AB	+	10MG	N009218	005		Mar	DISC
>A>		@	10MG	N009218	005		Mar	DISC

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

@ JAZZ PHARMS INTL 200MCG/2ML (100MCG/ML)

N021060	003	Dec 28, 2004	Feb	CAIN
---------	-----	--------------	-----	------

ZIDOVUDINE

INJECTABLE; INJECTION

ZIDOVUDINE

>D>	AP	LIAONING CHENGDA	10MG/ML	A204538	001	Nov 26, 2013	Mar	DISC
>A>		@	10MG/ML	A204538	001	Nov 26, 2013	Mar	DISC

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

>A>	AB	INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar	NEWA
>A>	AB		5MG	A204284	002	Apr 09, 2014	Mar	NEWA
	AB	TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb	NEWA
	AB		5MG	A090861	002	Mar 04, 2014	Feb	NEWA

ZONISAMIDE

CAPSULE; ORAL		ZONISAMIDE							
AB	ANI PHARMS INC	25MG	A 077639	001	Dec 22, 2005	Jan	CAHN		
	@	25MG	A 077641	003	Dec 22, 2005	Jan	CAHN		
AB		50MG	A 077639	002	Dec 22, 2005	Jan	CAHN		
	@	50MG	A 077641	002	Dec 22, 2005	Jan	CAHN		
AB		100MG	A 077639	003	Dec 22, 2005	Jan	CAHN		
	@	100MG	A 077641	001	Dec 22, 2005	Jan	CAHN		
	@ SANDOZ	25MG	A 077644	001	Dec 22, 2005	Feb	DISC		
	@	50MG	A 077644	002	Dec 22, 2005	Feb	DISC		
	@	100MG	A 077644	003	Dec 22, 2005	Feb	DISC		

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DRIXORAL PLUS

@ SCHERING PLOUGH	500MG;3MG;60MG	N019453	001	May 22, 1987	Feb DISC
-------------------	----------------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

IPCA LABS LTD	5MG	A202277	002	Mar 11, 2014	Feb NEWA
---------------	-----	---------	-----	--------------	----------

	10MG	A202277	004	Mar 11, 2014	Feb NEWA
--	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES

IPCA LABS LTD	5MG	A202277	001	Mar 11, 2014	Feb NEWA
---------------	-----	---------	-----	--------------	----------

	10MG	A202277	003	Mar 11, 2014	Feb NEWA
--	------	---------	-----	--------------	----------

TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ CARACO	5MG	A077631	004	Jan 11, 2008	Feb DISC
----------	-----	---------	-----	--------------	----------

@	10MG	A077631	003	Jan 11, 2008	Feb DISC
---	------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CARACO	5MG	A077631	001	Jan 11, 2008	Feb DISC
----------	-----	---------	-----	--------------	----------

@	10MG	A077631	002	Jan 11, 2008	Feb DISC
---	------	---------	-----	--------------	----------

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC	6MG;120MG	A078648	001	Feb 27, 2013	Jan CRLD
---------------	-----------	---------	-----	--------------	----------

DISOPHROL

@ SCHERING PLOUGH	6MG;120MG	N013483	004	Sep 13, 1982	Jan DISC
-------------------	-----------	---------	-----	--------------	----------

DRIXORAL

@ SCHERING PLOUGH	6MG;120MG	N013483	003	Sep 13, 1982	Jan DISC
-------------------	-----------	---------	-----	--------------	----------

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

TABLET;ORAL

ALEVE PM

+ BAYER HLTHCARE	25MG;220MG	N205352	001	Jan 17, 2014	Jan NEWA
------------------	------------	---------	-----	--------------	----------

IBUPROFEN

TABLET;ORAL

IBUPROFEN

>A>	AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Mar NEWA
-----	---------------	-------	---------	-----	--------------	----------

MINOXIDIL

AEROSOL, FOAM;TOPICAL

WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON	5%	N021812	002	Feb 28, 2014	Feb NEWA
-----------------------	----	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 3 MARCH 2014

NO MARCH 2014 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MARCH 2014 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	>A> 6488962	Jun 20, 2020	DP		>A> NP	Mar 03, 2017
	>A> 7976870	Jun 01, 2027	U-1498			
	>A> 8372432	Mar 11, 2029	DP U-1499			
	>A> 8377453	Nov 19, 2029	DP U-1499			
	>A> 8394408	Mar 11, 2029	DP			
	>A> 8597681	Dec 21, 2030	DP			
	>A> 8658631	May 16, 2032	DP			
	>A> 8668929	Mar 11, 2029	U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8653061	Aug 24, 2025	U-1373			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	6514980	Jan 24, 2019	DP U-1484			
	7223387	May 13, 2023	DP U-1006			
	7223387	May 13, 2023	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADENOSINE - ADENOSINE</u>						
A 077425 001					>A> PC	Mar 22, 2014
<u>ALCAFTADINE - LASTACAFI</u>						
N 022134 001	>A> 8664215	Oct 05, 2029	U-1493			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 001	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURNA</u>						
N 021985 002	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 001	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 002	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 003	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT</u>						
N 022107 004	8618172	Jul 13, 2028	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jan 23, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jan 23, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8645160	Jun 18, 2029	U-1485			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	>A> 6413980	Dec 22, 2019	DS DP U-1200		>A> I-681	Mar 03, 2017
	>A> 6413980	Dec 22, 2019	DS DP U-1501			
	>A> 6967208	Feb 03, 2023	DS DP U-1167			
	>A> 6967208	Feb 03, 2023	DS DP U-1200			
	>A> 6967208	Feb 03, 2023	DS DP U-1323			
	>A> 6967208	Feb 03, 2023	DS DP U-1501			
	>A> 6967208	Feb 03, 2023	DS DP U-1502			
<u>APREMILAST - OTEZLA</u>						
N 205437 001					>A> NCE	Mar 21, 2019
<u>APREMILAST - OTEZLA</u>						
N 205437 002					>A> NCE	Mar 21, 2019
<u>APREMILAST - OTEZLA</u>						
N 205437 003					>A> NCE	Mar 21, 2019
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 001	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 002	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 003	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 004	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021436 006	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPIRAZOLE - ABILIFY</u>						
N 021713 001	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 002	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 003	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	8642600	Jan 28, 2022	U-1492			
	8642600*PED	Jul 28, 2022				
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001					>A> NP	Oct 03, 2016
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	>A> 8546428	Mar 19, 2029	DS DP U-1321			
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	8663699	Jun 03, 2029	U-124			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8263054	Jan 15, 2023	U-1277			
	8632760	Jan 15, 2023	U-1487			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001					ODE	Jun 20, 2015
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	>A> 8669290	Jan 16, 2024	DP			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8616196	Apr 07, 2029	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8616196	Apr 07, 2029	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	>A> 8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	>A> 8658198	Dec 03, 2027	DP U-1494			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	>A> 8003353	Jun 11, 2024	U-817			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8633162	Aug 27, 2024	U-1479			
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024	U-1483			
>A>	8685930	Aug 27, 2024	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-678 ODE	Jan 08, 2017 Jan 09, 2021
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-678 ODE	Jan 08, 2017 Jan 09, 2021
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250 001	>A> 8663685	Jan 18, 2025	U-1030			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001					NCE	Jan 08, 2019
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002					NCE	Jan 08, 2019
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	>A> 8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	>A> 8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	>A> 8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	>A> 8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	>A> 8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	>A> 8680103	Feb 04, 2025	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					M-61 PED	Jun 17, 2016 Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078992 003					PC	May 18, 2014

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	>A> 8679544	Apr 23, 2030	DP			
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	>A> 8679544	Apr 23, 2030	DP			
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE	Feb 18, 2019
					ODE	Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 001					>A> PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 002					>A> PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 003					>A> PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 001					>A> PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 002					>A> PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 003					>A> PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 001					>A> PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 002					>A> PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 003					>A> PC	Jun 09, 2014
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					>A> NPP	Mar 20, 2017
					>A> PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					>A> NPP	Mar 20, 2017
					>A> PED	Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001					>A> NPP	Mar 20, 2017
					>A> PED	Sep 20, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	>A> 5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	>A> 5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	>A> 5877192*PED	Nov 27, 2014				
	>A> 6143771	May 27, 2014	DP U-643			
	>A> 6143771	May 27, 2014	DP U-1495			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	>A> 5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	>A> 5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	>A> 5877192*PED	Nov 27, 2014				
	>A> 6143771	May 27, 2014	DP U-643			
	>A> 6143771	May 27, 2014	DP U-1495			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	>A> 8617598	Sep 27, 2022	DP			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	>A> 8617598	Sep 27, 2022	DP			
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	>A> 8617598	Sep 27, 2022	DP			
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
<u>FLORBETABEN F-18 - NEURACEQ</u>						
N 204677 001	>A> 7907135	Mar 18, 2029	DS DP U-1497		>A> NCE	Mar 21, 2019
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	>A> 7270800	Jan 24, 2023	DS DP U-336		>A> NCE	Oct 25, 2018
	>A> 7351401	Jan 24, 2023	DS DP U-336			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	>A> 7270800	Jan 24, 2023	DS DP U-336		>A> NCE	Oct 25, 2018
	>A> 7351401	Jan 24, 2023	DS DP U-336			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8147461	Oct 15, 2028	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001					NP	May 10, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399	001				ODE	Jun 06, 2019
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399	002				ODE	Jun 06, 2019
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622	003	6054430	May 24, 2014	DS	>A> NP	Jan 28, 2017
		6342476	May 24, 2014	U-441		
		6362161	May 24, 2014	DS		
		7199098	May 24, 2014	DS		
		8232250	Aug 19, 2030	U-441		
		8367605	May 24, 2014	DS		
		8399413	Sep 06, 2030	U-441		
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284	001	8642012	Sep 22, 2030	U-1383		
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555	001	7348361	Nov 06, 2020	DP U-1087		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	001	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	002	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	003	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	004	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	005	6228398	Nov 01, 2019	DP		
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880	006	6228398	Nov 01, 2019	DP		
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	8476284	Dec 28, 2026	U-1456	I-680	Feb 12, 2017
		8476284	Dec 28, 2026	U-1491	ODE	Feb 12, 2021
		8497277	Dec 28, 2026	U-1456		
		8497277	Dec 28, 2026	U-1491		
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057	001				NP	Jul 26, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	001	RE43932	Jan 16, 2019	DS DP		
		RE43932*PED	Jul 16, 2019			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335	002	RE43932	Jan 16, 2019	DS DP		
		RE43932*PED	Jul 16, 2019			
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	001				NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768	002				NP	Feb 24, 2017
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986	005	6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536	005	6899699	Jan 02, 2022	DP		
		7686786	Aug 03, 2026	DP		
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081	002	>A> 8679069	Apr 12, 2025	DP		
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629	003	>A> 8679069	Apr 12, 2025	DP		
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454	001	>A> 5310912	Feb 25, 2015	DS		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8648107	May 28, 2024	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 001	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 002	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 003	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 004	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 005	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880 006	8626531	Oct 23, 2020	U-1210			
	8648095	May 15, 2023	U-1216			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001 >A>	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002 >A>	8673927	Aug 23, 2027	U-1503			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003 >A>	8673927	Aug 23, 2027	U-1503			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	8618135	Mar 07, 2025	U-1316			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7052679	Oct 26, 2021	DP			
	7537009	Oct 28, 2024	DP			
	8074644	Jul 25, 2022	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001 >A>	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002 >A>	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-134	May 24, 2016

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001				>A>	NP	Mar 24, 2017
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001				>A>	NCE	Mar 19, 2019
				>A>	ODE	Mar 19, 2021
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>NIACIN - NIACIN</u>						
A 076250 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 002					PC	Mar 19, 2014
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	>A> 8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	>A> 8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	>A> 8663680	Feb 13, 2020	DP			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002					M-132 PED	Dec 21, 2013 Jun 21, 2014
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003					M-132 PED	Dec 21, 2013 Jun 21, 2014
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	8642079	Mar 01, 2028	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8637540	Nov 26, 2023	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8637540	Nov 26, 2023	DP			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8658663	Apr 06, 2029	DS DP U-904			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Apr 20, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8626531	Oct 23, 2020	U-1361			
	>A> 8673939	May 15, 2023	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8626531	Oct 23, 2020	U-1361			
	>A> 8673939	May 15, 2023	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8626531	Oct 23, 2020	U-1361			
	>A> 8673939	May 15, 2023	U-1360			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8626531	Oct 23, 2020	U-1361			
	>A> 8673939	May 15, 2023	U-1360			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	>A> 8410077	Mar 13, 2029	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	>A> 8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	>A> 8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	>A> 8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	>A> 8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	>A> 8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	>A> 8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	>A> 8679533	Sep 08, 2029	DP U-219			
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	>A> 8338489	Oct 16, 2028	U-1496		>A> NP >A> ODE	Mar 14, 2017 Mar 14, 2021
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					>A> PC	Sep 24, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Jul 08, 2029	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8642573	Oct 02, 2029	U-1481			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8642573	Oct 02, 2029	U-1481			
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8618142	Mar 08, 2024	DP			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-134	May 24, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-134	May 24, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137 M-133	Jan 31, 2017 Jan 31, 2017

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109	001				D-137 M-133	Jan 31, 2017 Jan 31, 2017
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676	003				PC	Jul 15, 2014
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671	001	8618076 8633309	Dec 11, 2030 Mar 26, 2029	DS DP U-1470 DS DP U-1470		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	008	>A> 8672898 >A> 8684969	Jan 02, 2022 Oct 20, 2025	DP DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	009	>A> 8672898 >A> 8684969	Jan 02, 2022 Oct 20, 2025	DP DP		
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148	010	>A> 8672898 >A> 8684969	Jan 02, 2022 Oct 20, 2025	DP DP		
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923	001	8618141	Feb 11, 2023	U-1480		
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239	001	>A> 6174304 >A> 6251091 >A> 6280410 >A> 6681810 >A> 8241243 >A> 8491524	Dec 13, 2015 Dec 09, 2016 Mar 27, 2017 Dec 13, 2015 Aug 10, 2023 Nov 21, 2022	DP DP DP DP DP DP		
<u>TASIMELTEON - HETLIOZ</u>						
N 205677	001	5856529	Dec 09, 2017	DS DP U-1486	NCE ODE	Jan 31, 2019 Jan 31, 2021
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277	001	8623868	Feb 21, 2023	DP		
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088	001	5362718 5362718*PED RE44768 RE44768*PED	Feb 15, 2019 Aug 15, 2019 Feb 15, 2019 Aug 15, 2019	DS DP DS DP	Y	
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219	001	>A> 7718640 >A> 8338395	Mar 14, 2027 Feb 27, 2026	DP U-1500	>A> NP	Mar 05, 2017
<u>THALIDOMIDE - THALOMID</u>						
N 020785	001	8626531	Oct 23, 2020	U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	002	8626531	Oct 23, 2020	U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	003	8626531	Oct 23, 2020	U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785	004	8626531	Oct 23, 2020	U-1465		
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516	001	>A> 6645963	Dec 02, 2018	DP		
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214	001				>A> M-135	Feb 21, 2017
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	001	5753677	May 19, 2020	U-978		
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	002	5753677	May 19, 2020	U-978		
<u>TOLVAPTAN - SAMSCA</u>						
N 022275	003	5753677	May 19, 2020	U-978		
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635	001	8663683	Nov 16, 2027	DP U-106		

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8663683	Nov 16, 2027	DP U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001 >A>	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002 >A>	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003 >A>	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004 >A>	8652527	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005 >A>	8652527	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003					I-678 ODE	Jan 08, 2017 Jan 08, 2021
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001					NP	Dec 18, 2016
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8642608	Feb 06, 2022	U-1490			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001 >A>	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002 >A>	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003 >A>	8673921	Jun 05, 2022	DS DP			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001 >A>	8450372	Mar 18, 2028	U-892			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 03 - March 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>